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Ovarian cancer is the most lethal gynaecological malignancy. Of the four ovarian cancer 
subtypes - serous, mucinous, endometroid and clear cell - serous ovarian cancer is the most 
common, comprising around 70% of cases. The median stage of diagnosis of ovarian cancer is 
stage III and patients present with widespread metastasis, usually facilitated by peritoneal fluid 
accumulation in the abdomen (ascites). Live single cancer cells and aggregates from the ascites 
represent a population with the potential to become metastatic and are thought to be the main 
contributors to disease recurrence, displaying increased chemoresistance after traditional first 
line therapy, which consists of extensive tumour debulking followed by combination platinum 
and taxane chemotherapy. For this reason, research into potential therapeutic targets in this 
important cell population is critical for development of more efficacious treatments for ovarian 
cancer. The opportunity to re-purpose existing pharmaceuticals for use as chemotherapeutics 
is an idea that has gained traction recently in the medical research field. This method 
circumvents the requirement for lengthy target identification and validation and extensive 
toxicity testing. One class of drugs that are a possible candidate for use against ovarian cancer 
are the dihydropyridines, which are antagonists of voltage-gated calcium channels (CaV). In 
ovarian cancer, CaV have already been shown to play a role in malignant behaviours such as 
migration and proliferation, although most expression and functional data in the literature are 
from ovarian cancer cell lines. There has been very little research on the role of CaV in primary 
ovarian cancer cells. This work addresses the question of whether CaV are expressed in primary 
ovarian cancer cells and whether channels in ovarian cancer cells are functional, particularly 
in cells derived from malignant ascitic fluid. Here, the results from immunohistochemical 
staining of ovarian tumour sections and RT-qPCR using normal ovaries, tumours and cells 
derived from malignant ascitic fluid suggest that in the majority of cases, CaV1.2 and CaV1.3 
become expressed in ovarian cancer cells only after cells have been shed from the primary 
tumour. CaV1.2 and CaV1.3 mRNA is expressed in ascites derived cells, although the highest 
expression of these mRNAs was seen in a sample from a patient with mucinous ovarian cancer. 
In serous ovarian cancer cells from ascites, CaV1.2 protein was shown with flow cytometry to 
be highly expressed and immunofluorescent staining confirmed that this expression is localised 
to the nucleus. Functionally, dihydropyridine antagonism with nifedipine was found to prevent 
cell migration only in a 2-dimensional wound-healing model, whereas invasion of cell lines 
and ascites derived primary cells into basement membrane extract was unchanged. Cell lines 
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display differing apoptotic responses to nifedipine, which triggers apoptosis in SKOV-3 but no 
response in OVCAR-8 at the same concentration. To assess channel functionality, fluorescent 
measurement of cytosolic Ca2+ flux using Fluo4-AM was performed on cell lines in the 
presence of the CaV agonist Bay K8644 and patch clamp electrophysiology was performed on 
cell lines and malignant ascites derived cells. Both of these techniques confirmed that no 
detectable L-type CaV current is present in the ovarian cancer cell lines. CaV current was 
observed in cells derived from malignant ascites, from the mucinous sample. Transient receptor 
potential (TRP) currents were also detected in OVCAR-8 cells, as well as single cells and 
spheroids from the ascites derived mucinous sample and were most likely carried by the Ca2+-
selective TRPV5 or TRV6. These results suggest that functional L-type CaV are present in 
cancer cells from malignant ascites of patients with mucinous ovarian cancer. Although CaV1.2 
was nuclear expressed in serous samples, similar research from other cancers has shown that 
these channels may still function in migration, even when expression is restricted to the 
nucleus, although nuclear channels would not be amenable to therapeutic targeting. These 
results fit into a wider context of contemporary research which is placing a greater role for CaV 
and ion channels in cancer, although more research needs to be performed in ovarian cancer 
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In the UK, ovarian cancer (OC) is the sixth most common cancer in females and is also the 
fifth most common cause of cancer death in females (Cancer Research UK 2021). There has 
been little change in the overall mortality in this malignancy in the last decade and the 5-year 
survival rates range from 92.1% for patients diagnosed with stage 1 cancer, to only 25% for 
patients with stage III and IV cancer (Matulonis et al. 2016). OC is usually diagnosed later in 
life, with a median age of diagnosis of 63 years old (“Ovarian Cancer Statistics” 2013). Factors 
which increase the risk of developing OC include genetic predisposition (e.g. BRCA status), 
age, hormonal therapy use, infertility and nulliparity. In the UK, first-line treatment for OC 
involves extensive tumour debulking followed by platinum and paclitaxel combination 
chemotherapy (NICE 2020a). Despite most OC patients having tumors which are initially 
sensitive, the majority who receive platinum treatment will eventually relapse and develop 
tumours with platinum resistance (Markman 2000), (Zyl, Tang, and Bowden 2018). As such, 
this malignancy requires research into new treatments that can extend progression free survival 
in patients. 
There are three main types of OC, which are epithelial ovarian carcinoma (EOC), sex-cord 
stromal and germ cell tumours. Of the three, EOC tumours are the most common, comprising 
90% of total cases (Guppy, Nathan, and Rustin 2005). These carcinomas can be arranged into 
four distinct histological subtypes; serous (75%); mucinous (10%) and endometroid (10%), 
with the remaining 5% formed of clear cell and other less common subtypes (Holschneider and 
Berek 2000). EOC is also categorized into two main phenotypic groupings – type I: which 
includes low-grade serous, mucinous and clear cell cancer and type II: which includes high 
grade serous, endometroid and undifferentiated EOC (Scott et al. 2013). This system of 
categorization is based on many years of clinical observations and has been validated by 
epidemiological studies that describe different levels of risk associated with long-term use of 
non-steroidal anti-inflammatory drugs (decreased risk of type I) or tubal ligation and birth 
control pills (decreased risk of type II), (Terada, Ahn, and Kessel 2016). Each of the four main 
histological EOC subtypes is associated with a set of common mutations. However, high grade 
serous (HGSOC) which is the most common and lethal subtype, displays mutations in only 1 
gene consistently between patients – in TP53, which is a tumour suppressor involved in DNA 
repair, control of the cell cycle and apoptosis (Bakir and Gabra 2014). In addition to high grade 
serous tumours, there are also low-grade serous carcinomas (LGSOC), which possess a 
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different molecular signature, are indolent and have a better prognosis than HGSOC. OC can 
be either hereditary or sporadic. In contrast to the ~1% of women in the general population that 
develop OC, 55-65% of women that are heterozygous for the pathogenic germline BRCA1 
variant will develop OC by the age of 70 years (Antoniou et al. 2003), (S. Chen and Parmigiani 
2007), which accounts for around 10% of total cases. Although somatic mutations in BRCA 
genes are rare in sporadic OC, deficiency in the function of the BRCA protein is thought to 
occur in up to 82% of sporadic OC cases and may be a result of dysregulated epigenetic control 
of gene expression, alternative splicing or other genomic abnormalities (Landen, Birrer, and 
Sood 2008). 
1.1 Basic physiology of the ovary 
 
The ovaries are the female gonads and are an abdominal, intraperitoneal organ suspended by a 
portion of the broad ligament known as the mesovarium and attached to the uterus via the 
ovarian ligament (Sherwood 1988). In the blastocyst stage of the human embryo, primordial 
germ cells (PGC) are formed from proximal epiblasts, triggered by extra-embryonic signalling. 
PGC then travel via amoeboid migration to the genital ridge – the somatic precursor of the 
gonads. PGC (now known as oogonia) divide mitotically, giving rise to an average of 4-5 
million oogonia by the fifth month of gestation. In the final stage of gestation, oogonia undergo 
the first stages of meiosis and enter the dictyate stage – meaning they are held at prophase I 
(the phase in which genetic information is transferred between homologous chromosomes) and 
are whenceforth known as primary oocytes. These primary oocytes are then surrounded by a 
single layer of granulosa cells, forming a primary follicle. Primary oocytes that are not 
incorporated into follicles degenerate, leaving females with around 2 million primary follicles 
at birth (Maruo, Peng, and Mochizuki 1996). 
Throughout the duration of a woman’s fertile life (ages ~13-50 years old), the ovaries undergo 
constant monthly cycles through a follicular and luteal phase, controlled by hormone release 
from the hypothalamic-pituitary-gonadal (HPG) axis (Sherwood 1988). Each cycle is 
characterised by menstrual bleeding resulting from endometrial degeneration. The follicular 
phase involves growth of one primary oocyte as well as expansion and differentiation of 
surrounding follicular cell layers, in an oestrogen-dependent process known as follicle 
maturation. In this phase, outer thecal cells synthesise androgens under luteinising hormone 
(LH) stimulation, which are converted into oestrogens by inner granulosa cells under follicle-
stimulating hormone (FSH) control. Some oestrogen remains within the developing follicle 
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(antrum) and triggers follicular cell proliferation, and some enters the bloodstream and acts to 
control hormone release via feedback mechanisms at the hypothalamus and pituitary 
(Sherwood 1988). Directly adjacent to and enclosing the oocyte during follicular development 
is a layer of cumulus cells. These cells act to regulate oocyte growth, direct sterol biosynthesis 
and during a process known as cumulus expansion, produce a hyaluronic acid-rich matrix 
which is retained with the oocyte upon ovulation (Yokoo and Sato 2004) and is crucial for 
normal sperm penetration and fertilization to occur (Russell and Salustri 2006). 
Around midcycle, the primary oocyte (2n) undergoes the first meiotic division, forming a 
secondary oocyte (n). The follicle is now of sufficient size that the resulting high levels of 
plasma estrogen trigger a surge of LH from the pituitary which results in release of the 
secondary oocyte from the mature follicle through induction of protease release and rupture of 
the ovarian surface epithelium (OSE) (Loumaye et al. 1995). The oocyte then travels to the 
fallopian tube (FT) where fertilization can take place upon potential contact with a 
spermatozoon. Rupture of the follicle at ovulation signals the end of the follicular phase and 
the start of the luteal phase (Sherwood 1988). 
In the luteal phase granulosa and thecal cells remaining in the remnant follicle first collapse 
into the emptied antral space that is filled with partially clotted blood. These follicular cells 
form the corpus luteum in a process called luteinisation. The granulosa cells hypertrophy and 
are converted into very active steroidogenic tissue. These cells also release vascular endothelial 
growth factor (VEGF) which results in the corpus luteum becoming highly vascularised as 
blood vessels from the thecal region invade the luteinizing granulosa. These changes are 
appropriate for the corpus luteum’s function, which involves production and secretion of large 
amounts of progesterone, and lesser amounts of estrogen into the blood (Sherwood 1988). 
Estrogen secretion in the follicular phase followed by progesterone secretion in the luteal phase 
is essential for preparing the uterus to be a suitable site for implantation of the fertilized ovum. 
The corpus luteum becomes fully functional within 4 days after ovulation, but it continues to 
increase in size for another 4 or 5 days. If the released ovum is not fertilized and does not 
implant, the corpus luteum regresses within 14 days of its formation. The luteal cells degenerate 
and are phagocytized, vascular supply is withdrawn, and connective tissue rapidly fills in to 
form a fibrous tissue mass known as the corpus albicans. The luteal phase is over and one 




1.2 Aetiology of ovarian cancer (OC) 
 
In 1971, Fathalla proposed the ‘incessant ovulation’ hypothesis which posited that over a 
woman’s lifetime, the constant rupture of the ovarian surface epithelium (OSE) (Loumaye et 
al. 1995) during ovulation leads to an increased probability of errors in DNA synthesis upon 
OSE repair and malignant transformation within this cell population (Fathalla 1971). This 
hypothesis was strengthened by the observation that multiple pregnancies and combined 
estrogen-progesterone oral contraceptive use (both of which decrease the number of 
ovulations) lower the risk of developing OC (Whittemore, Harris, and Itnyre 1992). It was later 
suggested that these factors exert their protective effect through progesterone-mediated 
apoptosis of transformed cells when Rodriguez et al. showed that monkeys fed a diet containing 
progesterone displayed significantly higher levels of apoptosis in their OSE than control 
animals (24.9% vs. 3.8%, respectively), whereas those fed combined estrogen-progesterone 
contraceptives or estrogen alone showed no significant difference (Rodriguez et al. 1998). 
Further evidence for progesterone’s protective effect extending beyond anovulation includes 
reduced risk of OC in women who give birth to their last child at an older age, when the 
apoptotic action of progesterone is thought to affect a greater number of transformed cells 
(Whiteman et al. 2003). Although not all protective factors decrease the number of ovulations, 
studies analysing the relationship between OC risk and factors including age at menarche 
(Gong et al. 2013), breastfeeding (Tung et al. 2018) and nullparity (Bodelon et al. 2013) suggest 
that incessant ovulation is likely to be involved in the aetiology of OC. 
Contrary to Fathalla’s original hypothesis, it appears that carcinogenesis in OC may be more 
complicated than DNA synthesis errors in the OSE. Despite many years of research into 
ovarian inclusion cysts, no convincing precursor lesion has ever been found on the ovary and 
until recently there was still debate over the tissue of origin of HGSOC. However in 2001, after 
extensive analysis of dysplastic FT tissue taken from BRCA+ women undergoing prophylactic 
adnexectomy, Piek et al. proposed that the site of origin of most hereditary serous carcinomas 
may be the FT epithelium (Piek et al. 2001). This initial proposal led to the development of the 
SEE-FIM (sectioning and extensively examining the fimbriated end) protocol for risk-reducing 
salpingo-oophorectomies (RRSO) (Arora and Mahesh 2018). The current view is that the 
precursor of most serous malignancies is ‘p53 signature’ tissue found in the distal FT/fimbriae 
epithelia which is non-neoplastic, p53 immunoreactive (increased or null), shows evidence of 
DNA damage upon H2AX localisation and harbours specific p53 mutations (Folkins et al. 
19 
 
2009), (Labidi-Galy et al. 2017). Tissue containing these p53 signatures may then give rise to 
non-malignant lesions called serous tubal intraepithelial lesions (STILs), which may then 
progress to become malignant neoplasms called serous tubal intraepithelial carcinomas 
(STICs) (Carlson et al. 2008). STICS are formed of proliferating, non-ciliated epithelium which 
show nuclear stratification and pleomorphism. Other common characteristics include 
prominent nucleoli and mitotic figures. Immunohistochemical staining for Ki-67 (a marker of 
cell proliferation) reveals an increase proliferation index, whilst staining for p53 reveals either 
overexpression or a complete absence of this transcription within STIC lesions (R. Singh and 
Cho 2017). 
p53 signatures are found in a similar frequency in BRCA+ and normal FT (~25%) (Shaw et al. 
2009). Studies that implemented the SEE-FIM protocol after RRSO have confirmed that STIC 
in the distal FT/fimbriae are common in women with inherited BRCA1/2 mutations 
(Wethington et al. 2016) and exceedingly rare in cancer-free women with no genetic risk or 
history of HGSC (Meserve et al. 2017). Analysis of TP53 mutations has confirmed the clonal 
relationship between FT precursors and tubal, ovarian and primary peritoneal carcinomas and 
that STIC are the earliest form of these malignancies in both BRCA+ and sporadic cases 
(Kindelberger et al. 2007), (Labidi-Galy et al. 2017). The incidence of STIC in sporadic 
HGSOC patients is ~60% (Przybycin, Kurman, and Ronnett 2010), suggesting the other 40% 
of these cancers may arise from other malignant precursors in the FT or elsewhere. Indeed, 
studies have shown identical TP53 mutations can be observed between STILs and HGSOC 
metastases in patients where HGSOC/STIC were absent from the endosalpinx (Soong et al. 
2018), suggesting that more than one pathway of ‘precursor escape’ from the FT can lead to 
HGSOC. Interestingly, a mechanism by which progesterone could exert its aforementioned 
protective effect at the FT (rather than solely at the OSE, as it was originally assumed to), could 
be through induction of necroptosis of p53 defective FT epithelial cells (Wu et al. 2017). The 
consensus is that the FT is very likely to be the source of most serous carcinomas, although the 
cellular precursors may differ in their carcinogenic pathway. 
1.3 Potential targets for new ovarian cancer treatments – Ca2+ ion channels 
 
There have been some recent advances in chemotherapeutics used in EOC in the UK. 
Angiogenesis inhibitors such as bevacizumab can be used alone for up to 15 months after first 
line chemotherapy and confer modest increases in progression-free survival of up to 8 months 
(NICE 2013). More recently, PARP (poly ADP ribose polymerase) inhibitors such as olaparib 
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have been approved as maintenance therapy for HGSOC patients with germline BRCA 
mutations (NICE 2020b). 
Unfortunately, many of these new therapies are only beneficial to a small subset of patients. 
One possible way to prolong survival in a greater proportion of patients may be to find novel 
chemotherapeutics to replace or supplement traditional platinum taxane therapy in OC. 
Traditional cytotoxic chemotherapeutics have a number of debilitating side effects, including 
nausea, hair loss, nephrotoxicity and ototoxicity and OC patients receiving this treatment still 
show high rates of relapse, with 70% of patients diagnosed at stage III or above experiencing 
recurrence 18-24 months (median) after first line therapy (Ushijima 2010). An idea that several 
other research groups are exploring is the re-purposing of pre-existing pharmaceuticals for their 
potential anti-cancer properties (Pushpakom et al. 2018). The benefits of this include known 
dosage regimens and pathways of metabolism, as well as existing approval by regulatory 
authorities which allow for bypassing of the lengthy processes of drug development and clinical 
trials.  
1.3.1 Ion channels as drug targets in cancer 
 
Ion channels are integral membrane proteins that facilitate flow of physiological ions (Na+, K+, 
Cl-, Mg2+, Ca2+, HPO4
2- or HCO3
-)  across a lipid membrane (measured by the physical quantity 
‘flux’, which is the number of ions passing through the membrane per second, per area). The 
human genome contains at least 232 genes that code for pore-forming subunits of ion channels 
(Nayak et al. 2009), which may be found at the plasma membrane or any one of a number of 
organellar membranes. There are 4 main types of ion channel which are: simple leak channels; 
voltage gated channels; ligand gated channels and mechanically gated channels (Resta and 
Becchetti 2010). Although these classifications are useful in distinguishing the biomolecular 
properties of different channels, groups are not mutually exclusive, and specific channels may 
exhibit more than one type of gating in varying degrees of significance (Goldschen-ohm and 
Chanda 2017). 
Ion channels have a vast array of functions in humans, ranging from facilitation of electrical 
signal propagation in the central and peripheral nervous systems (voltage gated Na+ channels) 
(Jun Wang, Ou, and Wang 2017), to control of insulin secretion by β-cells of the endocrine 
system in response to an increase in blood glucose (ATP-sensitive K+ channels) (Koster, 
Permutt, and Nichols 2005). As a result of their crucial role in normal physiology, dysfunction 
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of ion channels caused by genetic or somatic channel alteration can cause diseases known as 
‘channelopathies’. The most common channelopathies result from mutations in ion channel 
genes and are often hereditary (J. Kim 2014). For example, the most common channelopathy 
in the Caucasian population is cystic fibrosis, a respiratory disease caused by inherited 
mutations in an ion channel called cystic fibrosis transmembrane conductance regulator 
(CFTR), that leads to insufficient Cl- release into the lumen of mucous membranes and 
increased viscosity of mucus (J. Kim 2014). 
As well as having roles at the tissue level, ion channels also play numerous roles at the cellular 
level, by facilitating migration (Jing Wang et al. 2014), (Fourbon et al. 2017), control of the 
cell cycle (Urrego et al. 2014), apoptosis (Bortner and Cidlowski 2014) as well as being 
involved in various signalling pathways between the extracellular environment and the 
cytoplasm and between the cytoplasm and the nucleus (Matzke, Weiger, and Matzke 2010). 
The dependence of cells on ions channels for so many indispensable cell processes means that 
aberrant alteration of ion channels either at the genetic or somatic level can trigger malignant 
transformation (Kunzelmann 2005). Of the ten hallmarks of cancer identified by Hanahan and 
Weinberg (Hanahan and Weinberg 2011), ion channels show strong association with four: 
induction of angiogenesis via VEGF signalling (Bernardini et al. 2019), resistance to apoptosis 
(Bortner and Cidlowski 2014), sustained proliferation (Urrego et al. 2014) and activation of 
invasion and metastasis (Kanwar et al. 2020). 
How cancer cells regulate the concentration and spatial restriction of ions is important in 
different hallmarks. For example, the global cellular K+ concentration is an important 
determinant of membrane potential (VM), which is itself vital for accurate cell cycle progression 
and sustained proliferation (Urrego et al. 2014). Changes in VM may take place over the 
timescale of hours, as K+ permeability gradually rises and falls with altered expression and/or 
function of K+ channels, triggering cell cycle progression through activation of cell-specific 
signalling pathways, regulation of cell volume and providing force for Ca2+ entry (in the case 
of increased K+ permeability) (Urrego et al. 2014). 
In the case of invasion and metastasis, Ca2+ channels are ideally placed to facilitate the 
signalling required for rapid sensing of the extracellular environment and responses enacting 
programs of cell motility. Ca2+ binds to water weakly and is able to precipitate phosphate, 
therefore in order to maintain cytoplasmic pH, cells must extrude, sequester, or chelate Ca2+ 
(Clapham 2007). This means there is a high gradient of extracellular to intracellular Ca2+ 
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(2*104-fold), which is ideal for both rapid signalling and long-term downstream effects, the 
latter in part facilitated by one of the many hundreds of proteins containing the Ca2+-binding 
EF hand domain, binding of Ca2+ to which causes conformational changes that facilitate 
progression of cell signalling pathways (Barbado et al. 2009). 
Two subfamilies of voltage gated Ca2+ channel (CaV) – the T-type CaV (CaT) and the L-type 
CaV (CaL) – are upregulated in OC cells with stem cell-like properties (Lee et al. 2020) and 
data from both OC and several other cancers has shown CaV to be vital contributors to 
malignant behaviours including cell proliferation and cell migration (reviewed extensively in 
the following sections). It is therefore possible that the dihydropyridines (DHP), which are a 
class of CaV antagonists used as anti-hypertensives, may be amenable to drug re-purposing. 
The chemical structure of some common DHP drugs is shown in figure 1 (Velena et al. 2016). 
There are few Ca2+ channel antagonists used currently as chemotherapeutics, although 
rituximab – a monoclonal antibody used in the treatment of B-cell lymphoma, targets two ion 
channels for therapeutic effect: the voltage gated K+ channel KV1.3 (L. H. Wang et al. 2012) 
and CD20, which is a Ca2+ ion channel (Tan et al. 2013). Antagonists of another class of Ca2+ 
ion channel are also being trialled in ovarian cancer. Blockade of members of the transient 
receptor potential family including TRPM7 (Déliot and Constantin 2015) and TRPV6 (Xue et 
al. 2018) results in anticancer activity in vitro and SOR-C13, a specific, synthetic peptide 
antagonist of TRPV6 has shown anti-tumour activity in ovarian cancer in phase I clinical trials 



























1.3.2 Voltage-gated Ca2+ channels 
 
Voltage-gated Ca2+ channels (CaV) are a family of plasma-membrane spanning ion channels 
that facilitate Ca2+ influx into cells when activated at specific membrane potentials (VM). Early 
electrophysiological research placed CaV into two types: low-voltage activated (LVA) channels 
that activate at VM positive to -70 mV (Alaoui et al. 2017) and high-voltage activated (HVA) 
channels that activate at VM positive to -40 mV (Marcantoni et al. 2010). Single-channel 
recordings of LVA channels showed low current amplitude and fast decay, so they were named 
T-type (CaT) channels (for tiny and transient), whereas HVA showed high current amplitude 
and slow decay kinetics and were named L-type (CaL) channels (for large and long-lasting). 
Three other types of CaV channel were subsequently identified in neuronal cells and designated 
N (neuronal), P/Q (Purkinje) and R (resistant) based on their sensitivity to peptide toxins 
derived from spiders and snails (Lacinová 2005). The homology between amino acid sequences 
of different CaV channels is shown diagrammatically in figure 3.  
Figure 1. The chemical structure of the dihydropyridine (DHP) drugs. First generation DHP: A – Nifedipine, B – 
Nicardipine. Second generation DHP: C – Benidipine, D – Felodipine. Third generation DHP: E – Amlodipine, F – 





There are four related isoforms of CaL channels – CaV1.1-1.4, which are all encoded by separate 
genes. Normal tissues that CaL are expressed in include skeletal muscle for CaV1.1 
(CACNA1S), vascular smooth muscle (VSM), the heart (Harvey and Hell 2013), adrenal 
chromaffin cells and neurons for CaV1.2 (CACNA1C), the heart, chromaffin cells, neurons, 
pancreas and kidney for CaV1.3 (CACNA1D) and the retina for CaV1.4 (CACNA1F) (Catterall 
2011). Depending on the anatomical location, CaL exist as tetramers or pentamers of several 
different ɑ1, ɑ2, β, δ and γ subunits (Catterall 2011). The ɑ1 is the main pore-forming subunit 















CaL consist of 4 transmembrane domains (TMD), each of which is formed of 6 transmembrane 
segments (TMS). Between TMS5-6 is a re-entrant loop that acts as a Ca2+ ion selectivity filter, 
containing amino acids that bind three Ca2+ ions and facilitate Ca2+ current in the activated state 
(L. Tang et al. 2014). TMS4 is a voltage-sensor that contains positive arginine and lysine 
Figure 2. Schematic representation of the secondary protein structure of a generic voltage gated Ca2+ channel α-
subunit. TMD – transmembrane domain, TMS – transmembrane segment 
Figure 3. CaV channel amino acid sequence similarity using CLUSTAL (adapted from the International Union of 





residues that respond to membrane depolarisation with a conformational change that results in 
channel pore opening (Waitkus-Edwards et al. 2002). CaL undergo voltage-dependent 
inactivation at VM around 0 mV (Marcantoni et al. 2010). CaL also undergo Ca
2+ dependent 
inactivation, which involves binding of Ca2+-calmodulin to the intracellular carboxyl tail of the 
channel (Peterson, Demaria, and Yue 1999). Other levels of control that affect the 
electrophysiological properties of CaL include tissue-specific alternative splicing (A. Singh et 
al. 2008), (Z. Z. Tang et al. 2009) as well as other cell-specific effects that result from molecular 
interactions. For example Th2 lymphocytes express CaL with activation kinetics that are 
insensitive to VM but are activated via interaction with PKCα (Robert et al. 2013). The 
CACNA1C gene also contains a cryptic promoter for a transcription factor at its 3’ end (Gomez-
Ospina et al. 2013) which in neurons is known to control expression of a suite of genes involved 
in excitability (Gomez-Ospina et al., 2006). The CACNA1D gene also has an associated 
transcription factor at its 3’ end (Lu et al., 2015), although it is unknown whether this is 
generated at the transcriptional level or results from enzymatic cleavage of the CaV1.3 protein. 
In addition to DHP, CaL are sensitive to phenylalkylamine (PAA) and benzothiazepine (BTP) 
antagonists (Grace and Camm 2000). DHP ligands can act as antagonists (e.g. nifedipine) or 
agonists (e.g. BAY K8644) depending on their chemical structure (Leung et al. 2014). The 
proposed mechanism of DHP antagonism involves ligand binding to amino acid residues in 
TMD3-S5 and S6 and TMD4-S6 which results in the stabilization of a non-conducting channel 
state in which a single Ca2+ ion is bound (Tikhonov and Zhorov 2009). Due to their vasodilatory 
action at VSM, DHP are used clinically in the management of hypertension (A. L. Wang, 
Iadecola, and Wang 2017). First generation DHP including nifedipine and nicardipine have a 
rapid onset and a short plasma half-life and were clinically associated with baroreflex-induced 
increases in heart rate that limited their efficacy. Second generation DHP such as benidipine 
and felodipine were created with longer half-life that reduced the acute baroflex response for 
better control of therapeutic effect. Third generation DHP such as amlodipine and barnidipine 
had substantially lower affinity for cardiac CaL, were more lipophilic and displayed more stable 
pharmacokinetics. The current fourth generation of DHP which include cilnidipine and 
lercanidipine are highly lipophilic and are now used in a wide range of conditions including 
myocardial ischaemia and congestive heart failure (A. L. Wang, Iadecola, and Wang 2017). 
DHP are already used clinically for management of hypertension in cancer patients receiving 
anti-angiogenesis therapy via systemic inhibition of VEGF signalling (Spano 2009) and there 
are in vitro studies that suggest DHP possess anti-cancer properties (Wong et al. 2020). 
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Crucially, meta-analysis of available data also suggests that there is no association between use 
of DHP and cancer incidence (Mason 1999). There is less evidence for potential association of 
CaT antagonism and cancer, as no truly specific inhibitors are used clinically and there are no 
studies analysing risk of ethosuximide, an anti-epileptic thought to target CaT in hypothalamic 
neurons (Hanrahan and Carson 2020).  














Another large family of cation-selective ion channels that facilitate Ca2+ influx are the transient 
receptor potential (TRP) channels. TRP channels are encoded by at least 28 separate genes, 
each of which code for a single TMD with 6 TMS and a re-entrant loop between TMS5-6 
(similar to the structure of a single CaV TMD). TRPs are grouped into 6 subfamilies based on 
phylogenetic analysis: TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA 
(ankyrin), TRPML (mucolipin) and TRPP (polycystin) (figure 4). Many of these channels may 
be found as homomeric or heteromeric complexes composed of members of either the same or 
a different TRP subfamily (Zheng 2013). Most TRP channels are non-selective cation channels 
Figure 4. A – The mammalian Transient receptor potential (TRP) ion channel family tree. Branch lengths indicate 
point-accepted mutations PAM (the mean number of amino acid substitutions per 100 residues) and represents 
evolutionary distance. Modified from Clapham (2003) ‘TRP channels as cellular sensors’ Nature 426: 517-524. B – 





with permeability (p) PCa/PNa ≤ 10 except for TRPM4 and TRPM5 which are monovalent 
specific and TRPV5 and TRPV6 which are Ca2+ specific (PCa/PNa >100) (Clapham et al. 2003). 
Different TRP channels are activated by a wide range of stimuli including voltage, heat, 
mechanical force, and chemicals including capsaicin – the major active vanilloid in chilli 
peppers (Panchal, Bliss, and Brown 2018). Some TRP channels display almost universal 
expression in different tissues, whereas others display expression specific to their function. 
TRPV1 for example is expressed in peripheral and central nerve terminals of sensory neurons, 
suited for its role in transmission of pain signals from spicy food (Premkumar and Sikand 
2008). 
Whilst TRP channel antagonists are not used clinically, several potential candidates have 
entered clinical trials for their analgesic effects, including antagonists of TRPV1, TRV3 and 
TRPA1 (Kaneko and Szallasi 2013). Agonists of TRPA1 have also shown promise in clinical 
trials for use as anti-dysphagia agents that improve swallowing function (Tomsen et al. 2020). 
1.4 The roles of CaV in malignant behaviour of cancer cells 
 
In cells from different cancers, CaV are thought to be important primarily for two malignant 
behaviours – cell proliferation and migration (Varghese et al. 2019). CaT show a high 
association with proliferation in ovarian cancer (Dziegielewska et al. 2016), (Wei Li et al. 
2011) as well as in prostate (Silvestri et al. 2019) and melanoma (Barcel et al. 2020). CaL are 
most frequently associated with migration and invasion in ovarian cancer, as well as breast 
cancer (Jacquemet et al. 2016), colon (Fourbon et al. 2017) cancer, and head and neck 
squamous cell carcinoma (Grasset et al. 2018). 
1.4.1 Cell migration 
 
Migration describes the normal process of cell movement and invasion describes movement 
that requires some alteration of the environment to progress. Whilst these are distinct processes, 
knowledge of these different types of cell motility in the level of detail required for the present 
work is not advanced enough to warrant any distinction cell migration will hitherto refer 
primarily to simple movement of cells unless stated otherwise. There are two main modes of 
cell migration that are frequently observed in studies using mammalian cells – amoeboid and 
mesenchymal (Clancy et al. 2019). These modes of migration are not firmly set however and 
there is evidence that cancer cells are able to adapt and switch between the two depending on 
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the rigidity of the extracellular matrix (ECM) with which they interact, with stiff matrices 
favouring mesenchymal type migration and softer matrices favouring amoeboid type 
(Sedgwick et al. 2015). Cells undergoing amoeboid cell migration are round, with a high 
membrane tension maintained by a cortical distribution of the actin cytoskeleton and display 
formation of ‘constriction rings’ – structures that allow cells to squeeze through small pores in 
ECM without the clustering of integrins (Wolf et al. 2002). Some cells undergoing amoeboid 
migration also release extracellular vehicle which aid in their migratory capacity (Clancy et al. 
2019). While it is known that cells from several different cancer types utilise amoeboid 
migration in vivo (Condeelis, Segall, and Einstein 2003), (Pettee et al. 2014), (Rintoul and Sethi 
2002), many of the biochemical mechanisms of cell migration that have been elucidated in 
recent years have used mesenchymally migrating fibroblasts as an experimental model. 
During mesenchymal cell migration, the cytoplasmic Ca2+ concentration ([Ca2+]C) is subject to 
tight spatio-temporal regulation which allows fine control of subcellular processes including 
cytoskeletal dynamics (Kanwar et al. 2020), turnover of focal adhesions (Franco et al. 2004) 
and contraction of the rear of the cell (Tsai and Meyer 2012). In this process, chemotactic 
growth factor signalling polarizes cells and gives them a defined front-rear axis with a leading 
edge consisting of dynamic actin-rich protrusions called lamellipodia, followed by a broader, 
more stable region containing actin bundles known as the lamella (Ponti et al. 2004). The most 
intensely studied mechanism of cell migration involves binding of growth factors such as 
platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth 
factor (FGF) and vascular endothelial growth factor (VEGF) to their respective receptor 
tyrosine kinase (RTK) which triggers activation of phospholipase C-γ (PLC-γ) and formation 
of inositol trisphosphate (IP3) (T. Y. Huang et al. 2018). Binding of IP3 to members of the IP3 
receptor (IP3R) family located at the endoplasmic reticulum (ER) is thought to sensitize 
receptors nearest to the chemotactic signal to undergo Ca2+-induced Ca2+ release (CICR), 
which are pulsatile localised increases in [Ca2+]C that occur upon stretch-induced Ca
2+ influx 
through plasma membrane channels of the TRP family (Wei et al. 2009). Many studies have 
also observed a front-rear increasing Ca2+ gradient in mesenchymally migrating cells, 
facilitated by high plasma membrane ATPase-mediated Ca2+ clearance at the leading edge as 
well as plasma membrane Ca2+ influx at the rear of the cell. In order for migrating cells to retain 
sensitivity to external chemotactic stimuli, the Ca2+ lost from the ER (the majority of which is 
subsequently pumped out of the cell by plasma membrane Ca2+-ATPase or ‘PMCA’) must be 
replenished. This is facilitated by stromal interaction molecule (STIM), which is an ER Ca2+ 
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sensor that oligomerizes when ER Ca2+ stores are low. STIM translocates to ER-plasma 
membrane junctions and triggers activation any of three Ca2+ channels named ORAI1-3, which 
replenish cytoplasmic Ca2+ upon activation (Y. Wang et al. 2009). 
There are several Ca2+-dependent processes involved in rear retraction that are facilitated by 
CaV in different normal mesenchymal cell types. CaL are required for PDGF-induced migration 
of mouse embryonic fibroblasts, where Ca2+ influx through CaL triggers calmodulin-mediated 
activation of myosin light chain kinase (MLCK) and contraction of actin fibres at the cell rear 
(S. Yang 2005). CaL are necessary for migration of A7r5 rat aortic smooth muscle cells in 
response to PDGF (Guo et al. 2018) and are also located at the rear of migrating human 
endothelial cells, where in addition to their role in rear contraction, they facilitate Ca2+ 
‘sparklets’ that establish the front-rear increasing Ca2+ gradient important for maintaining the 
sensitivity of the contraction machinery to the directional signal (Man et al. 2016).  
When compared to normal cells, the role of CaV in cancer cell migration is more variable 
between cell types. For example, although rear-localised Ca2+ sparklets have been observed in 
the mesenchymally-migrating MDA-MB-231 breast cancer cell line (Man et al. 2016), 
concentrations of nifedipine on the order of 100 µM are required to hinder their motility. 
However, when cells are subject to knockdown (KD) of ITPR1 (the gene coding for the inositol 
1,4,5-trisphosphate receptor 1, an intracellular Ca2+-release channel), the concentration of 
nifedipine required to inhibit migration in knockdown cells falls to 10 µM, suggesting that CaV 
may also be able to compensate for defects in intracellular Ca2+ release in migrating MDA-
MB-231 cells (Chovancova et al. 2020). 
RNA interference experiments (RNAi) and DHP antagonism have also shown that CaL-
mediated Ca2+ influx correlates with filopodia stability in MDA-MB-231 cells. Filopodia are 
actin-rich protrusions of the lamellipodia that begin the process of mesenchymal-type cell 
migration by ‘scanning’ the extracellular environment at the leading edge and forming focal 
adhesions (Pan 2010). In several 3D spheroid-based experiments, CaV1.3-mediated Ca
2+ influx 
at nascent filopodia was shown to be a result of a signalling cascade involving integrin β1 and 
subsequent src activation which leads to Ca2+ influx via an unknown mechanism that is not 
dependent on direct channel phosphorylation (Jacquemet et al. 2016). 
The observation that functional CaL exist at both the rear and filopodia of MDA-MB-231 breast 
cancer cells suggests that these channels may be involved in both physical movement of cells 
in 2D models through actin filament contraction and sensing of the extracellular environment 
30 
 
in 3D models. Cancer cell spheroids display differential expression of genes to cells found as 
monolayers (Francia et al. 2004) and it is possible that CaV may play a different role in single 
cells to that seen in multicellular aggregates. 
CaL may also facilitate migration by a mechanism that is independent of Ca
2+ influx through 
the channel. In the colorectal carcinoma cell line HCT116, use of 10 µM nifedipine increased 
whereas 10 µM verapamil decreased cell migration in both a wound healing assay (WHA) and 
a transwell invasion assay (TIA). Although KD of CaV1.3 (confirmed to be the dominant CaL 
subtype in colon cancer by immunohistochemical staining of tumour sections) did abrogate 
migration of these cells, subsequent patch-clamp electrophysiological recording could not 
detect any appreciable CaL current. In addition, fluorometric measurement of [Ca
2+]C changes 
induced by increasing external [K+] revealed that whilst depolarisation did not induce any 
increase in [Ca2+]C in these cells, knockdown of CaV1.3 did reduce the baseline [Ca
2+]C. 
Decreasing external [Ca2+] also had no effect on [Ca2+]C in either CaV1.3 knockdown (KD) or 
WT cells whereas treatment with thapsigargin (a sarco/endoplasmic reticulum Ca2+ ATPase 
inhibitor) did reveal a reduced [Ca2+]C peak in CaV1.3 knockdown cells. These data confirm 
that in HCT116 cells, CaV1.3 controls [Ca
2+]C at least partially through activity at the ER, 
independent of activity at the plasma membrane (Fourbon et al. 2017). 
The role of CaL in migration in OC cells is less well studied. CaV act upstream of the MAPK 
pathway to facilitate migration in OVCAR-3 ovarian cancer cells treated with the 
chemoattractant gonadotropins (GT) FSH or LH. Use of 25 µM verapamil blocks 
phosphorylation of ERK1/2 induced by 10 nM FSH/LH treatment in these cells and inhibits 
migration in both a WHA and a TIA. ERK1/2 phosphorylation was also shown to be dependent 
on a) intracellular Ca2+ release using the ryanodine receptor antagonist dantrolene and b) PKCδ 
activation (Mertens-Walker et al. 2010). It is thought that CaV-mediated Ca
2+ influx activates 
PKCδ, which phosphorylates ERK1/2 - kinases which phosphorylate many downstream targets 
involved in cell migration including MLCK (Vijayan et al. 2003), focal adhesion kinase (FAK) 
(Hunger-Glaser et al. 2003) and m-calpain (Glading et al. 2004).  
A direct connection between CaL and migration has been shown in SKOV-3 cells, where DHP 
antagonism with nifedipine prevents 2D migration of cells in response to the chemoattractant 
lysophosphatidic acid (LPA). This pathway is thought to be reliant on calmodulin, Ca2+-
calmodulin dependent kinase II (CaMKII) and RhoA activation which leads to formation of 
the focal adhesions required for mesenchymal-type migration (E. K. Kim et al. 2014). 
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1.5 The possible roles of CaL in the ovarian tumour microenvironment (TME) 
 
The ovaries are intraperitoneal and are suspended by a portion of the broad ligament known as 
the mesovarium (Sherwood 1988). Metastasis to the peritoneal cavity is common in stage II 
and III HGSOC (Chandrashekhara, Triveni, and Kumar 2016) and primary HGSOC tumours 
may also spread to the bladder or the large bowel. Other common sites of metastases presenting 
in patients with stage III/IV HGSOC include the lymph nodes, uterus, fallopian tubes and the 
omentum – a large flat layer of adipose tissue that covers the abdominal organs and performs 
immune surveillance of the abdomen (Halkia, Spiliotis, and Sugarbaker 2012). The most 
common mechanism of metastasis involves sloughing off of single cells or spheroids 
(aggregates of tens to thousands of cells) from the primary tumour, which then float in the 
peritoneal fluid. Deposition of cancer cells in the abdomen may be facilitated by ascites, which 
is an accumulation of fluid in the peritoneal cavity that occurs in around a third of HGSOC 
patients (Ayantunde and Parsons 2007). Malignant ascites is characterised as an exudative 
ascites, which develops through obstruction of lymphatic vessels preventing normal drainage 
of intra-abdominal fluid, combined with a microenvironment rich in vascular endothelial 
growth factor (VEGF) which increases the permeability of sub-mesothelial blood vessels 
(Martin-Hirsch, Preston, and Tomlinson 2014). Malignant ascitic fluid (MAF) from patients 
with HGSOC contains a myriad of different biological entities including cells, signalling 
molecules such as cytokines (Moradi et al. 1993), (Giuntoli et al. 2009), chemokines and 
growth factors (Sowter, Corps, and Smith 1999), (Hikita et al. 2011), (Yagi et al. 2005), 
extracellular matrix molecules (Ahmed and Stenvers 2013) and extracellular vesicles 
(Nakamura et al. 2019). 
1.5.1 Tumour microenvironment – Cells 
 
HGSOC MAF harbours various cell types, including cancer cells (29.1%), leucocytes (42%), 
cancer associated fibroblasts (CAF, 26.1%) and endothelial cells (2.8%) (Q. Gao et al. 2019). 
The different types of leucocytes include CD8+ and CD4+ T cells, CD20+ B cells, regulatory T 
cells (Treg), M1 and M2 macrophages and rare plasmacytoid dendritic cells (Ahmed and 
Stenvers 2013). Peritoneal mesothelial cells and cancer associated adipocytes (CAA) are also 
found in lower numbers in MAF (Ahmed and Stenvers 2013). 
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In LGSOC ascitic fluid, the aforementioned proportions of different cell types are similar for 
cancer cells and endothelial cells (25.5% and 8.5%, respectively) however leucocytes display 
a modest increase (54.5%) and CAF a marked decrease (11.5%) (Q. Gao et al. 2019). 
1.5.2 Tumour microenvironment – Cells – Cancer-associated fibroblasts (CAF) 
 
The difference in ascitic cellular burden of CAF between LGSOC and HGSOC may reflect 
some contribution that these cells make towards development or maintenance of HGSOC. CAF 
are also thought to compose ~10-60% of ovarian tumour volume (Dasari, Fang, and Mitra 
2018). They are consistently found at the centre of spheroids from patients with HGSOC and 
contribute to their formation and resistance to anoikis – the specific type of apoptosis that 
usually occurs upon loss of integrin-mediated cell-matrix contact (Q. Gao et al. 2019). CAF 
are critical modulators of tumour cell behaviour, facilitating invasion, tumour cell growth and 
survival through mechanisms including deposition and remodelling of extracellular matrix 
molecules, paracrine signalling, secretion of proteases and direct cell-to-cell signalling (Dasari, 
Fang, and Mitra 2018). 
Few studies have specifically addressed expression of L-type CaV in CAF, although induction 
of a CAF phenotype in human mammary fibroblast cells through treatment with transforming 
growth factor beta (TGFβ) is associated with a significant increase in CaV1.2 (L-type) and 
CaV3.2 (T-type) and DHP antagonism with nimodipine decreases CAF induction (Sadras et al. 
2020). Given the aforementioned role for CaV in normal fibroblasts, it is likely that these 
channels play some role in migration of CAF, although more research is required to determine 
this. 
1.5.3 Tumour microenvironment – Cells – Cancer-associated adipocytes (CAA) 
 
Whilst not found in large number in MAF, adipocytes are a major cell type of the omentum 
and are a key cell type of the TME, promoting resistance of cancer cells to chemotherapeutics 
such as cisplatin via secretion of arachidonic acid, which activates the Akt pathway and inhibits 
apoptosis (J. Yang et al. 2019). Cancer associated adipocytes (CAA) are able to transfer free 
fatty acids to cancer cells and promote their utilization of β-oxidation, meaning CAA also serve 
as an energy source for rapid tumour growth (Nieman et al. 2011). 




Tumour-infiltrating lymphocytes (TIL) are a common cell type within the ovarian tumour 
microenvironment (Giuntoli et al. 2009) and TIL burden is positively correlated with patient 
survival (Bowtell et al. 2016). In cancers such as melanoma and non-small cell lung cancer, 
TIL are critical facilitators of immune checkpoint therapy, which uses antibodies to block the 
immune response dampening CTLA4 (cytotoxic T-lymphocyte-associated protein 4) receptor 
on cytotoxic T cells to increase immune cell killing of tumour cells. However, this therapy 
relies on the presence of neoantigens – proteins resulting from mutant genes that are recognised 
as abnormal and stimulate an immunogenic response. Genetically, HGSOC is a cancer 
characterised predominantly by copy number alterations and a relatively low mutation burden 
and is therefore not amenable to this type of therapy (Martin et al. 2016), (R. Y. Huang et al. 
2012). In addition, research has shown that many TIL in the tumour microenvironment may be 
‘exhausted’ by excessive antigen stimulation and/or constant cytokine signalling (Bowtell et 
al. 2016). 
Tumour-associated macrophages (TAM) of the M2 subtype are also found throughout 
spheroids from ovarian MAF and are thought to promote spheroid formation and early 
transcoelomic metastasis (Yin et al. 2016). Although a high M1/M2 ratio predicts longer 
survival in OC (M. Zhang et al. 2014), the majority of TAM in MAF are of the immune-
suppressing M2 subtype and contribute to spheroid invasiveness (Raghavan et al. 2019), 
possibly through ECM remodelling (Finkernagel et al. 2016). 
CaL are not thought to be highly expressed in macrophages (Desai and Leitinger 2014), 
although more studies of expression are required to confirm that this is also the case with 
macrophages from ovarian MAF. L-type CaV are expressed by Th2 lymphocytes which express 
CaV1.2 and CaV1.3 (Kotturi et al. 2003), (Stokes, Gordon, and Grafton 2004). It remains to be 
determined whether antagonism of leucocyte CaL has any detrimental effects and whether or 
not these would be outweighed by their beneficial effects on cancer progression. 
1.5.5 Tumour microenvironment – Cells – Cancer cells 
 
Ovarian cancer cells from MAF may be found as single cells or spheroids (Latifi et al. 2012). 
The majority are thought to retain an epithelial phenotype, with high expression of E-cadherin. 
Ovarian spheroids from the same patient are also heterogenous in their binding and 
disaggregation on different ECM components - most spheroids from MAF will disaggregate 
when plated on collagen-1 for 24 hours, whilst others remain unaltered (Burleson et al. 2006). 
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Several recent studies have modelled the mechanism of spheroid disaggregation onto 
mesothelial cells of the peritoneum and have shown that cancer cells exert force on mesothelial 
cells to clear an invasive path and also induce migration of mesothelial cells in contact with the 
spheroid away from the area (Iwanicki et al. 2011). 
There are known subpopulations of cancer stem cells (CSC) in MAF and markers used to 
distinguish these include CD24, CD44, CD117, CD133 and ALDH. When used as markers for 
cell sorting, only CD133 and ALDH display significantly higher tumorigenic capacity at lower 
cell numbers than unsorted cells (Kryczek et al. 2012), (Silva et al. 2011). CaL are upregulated 
in A2780 stem cells and DHP inhibition prevents spheroid formation, decreases stemness and 
proliferation and promotes apoptosis in these cells (Lee et al. 2020). 
Few studies have studied expression of CaV in ovarian tumours, although one study has shown 
significant underexpression of CaL in late stage tumours when compared to early stage 
(Yoshihara et al. 2009). The presence of these channels in cancer cells from ascites is unknown. 
Tumour-derived OC cell lines including the A2780 and IGROV-1 do express CaT and 
mibefradil and RNAi decreases proliferation and increases apoptosis (Dziegielewska et al. 
2016). Given the aforementioned role of CaV in the migratory response of OVCAR-3 to 












Figure 5. Exosome biogenesis. A) The first stage of exosome formation involves activation of cell-specific receptors and 
subsequent plasma membrane invagination which forms primary endocytic vesicles (PEV). B) PEVs then fuse to form early 
endosomes (EE). B1/C) EEs then enter one of two pathways – they either become ‘recycling endosomes’ (RE) which results in 
return of the membrane lipids to the plasma membrane or they change into ‘late endosomes’ (LE) which are characterised by 
formation of nascent exosomes (called intraluminal vesicles), which form upon fusion of the EE membrane and result in 
internalisation of cytosolic cargo including proteins, nucleic acids and lipids. C1/D) the LEs are then either destroyed upon 
fusion with lysosomes or dock with the plasma membrane to release their exosomes (Mashouri et al. 2019). 
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Exosomes are 30 – 150 nm diameter extracellular lipid vesicles that facilitate cell-to-cell 
signalling and transfer of cargo between the cells in MAF (Nakamura et al. 2019). Exosome 
biogenesis is summarised in figure 5. There is little evidence of exosomes in shedding of cancer 
cells from the primary tumour. However, human peritoneal mesothelial cells (HPMC) can 
internalise exosomes produced by OC cell lines and pre-treatment of HPMC with cancer cell-
derived exosomes potentiates the ability of cancer cells to perform mesothelial clearance. This 
enhanced clearance is a result of HPMC expression of exosome-derived CD44 protein and 
subsequent upregulation of matrix metalloproteinase 9 (MMP9), which facilitates invasion 
through clearance of extracellular matrix molecules such as collagen IV and V. High CD44 
expression is also observed in HPMC cells from omental metastases in 60% of stage III/IV 
HGSOC patients, whilst normal omental HPMC are mainly negative (Nakamura et al. 2017). 
Exosomes derived from CAF contain a greater concentration of TGFβ1 than their counterparts 
from normal omental fibroblasts and also impart increased invasive and migratory capacity 
upon SKOV-3 and CAOV-3 OC cells upon uptake (Wenqian Li et al. 2017). In addition to 
cytokine cargo, patient-derived CAF and cancer associated adipocytes (CAA) have been shown 
to release exosomes containing miRNAs such as miR-21, which stimulates increased invasive 
capacity in OC cell lines through knockdown of APAF1 (apoptotic protease activating factor 
1) – a protein with a key role in apoptosis (Lam et al. 2016). 
It is thought that exosome release is a Ca2+-dependent process. In breast cancer MDA-MB-231 
cells, treatment with ionomycin (a compound that results in increased intracellular Ca2+) leads 
to increased exosome release, which was also shown to be dependent on Munc13-4 – a Ca2+ 
binding protein that facilitates interaction of vesicles with the plasma membrane before release 
(Messenger et al. 2018). 
Another class of extracellular vesicle that play a direct role in cancer cell invasion are the 
tumour microvesicles (TMV). These vesicles differ from exosomes in that they result from 
direct outward budding and pinching of the tumour cell plasma membrane (Lam et al. 2016). 
Amoeboid ovarian cancer cell lines release TMVs that contain matrix-metalloproteases that aid 
in proteolytic degradation of ECM during migration (Raposo et al. 2015). 
1.6 Electrophysiology and measurement of Ca2+ influx into cells 
 
In order for cells to remain viable, they must expend energy derived from metabolic processes 
on maintaining gradients of ions across their plasma membrane. In addition to the potential 
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energy stored in the concentration gradient as a result of thermodynamic considerations, ions 
are charged species and their separation also results in a difference in electrostatic potential 
energy (a voltage). In most cells, these electrochemical gradients are generated mostly by 
sodium-potassium ATPase pumps, which are active transporters that export three Na+ and 
import two K+ against their electrochemical gradients. In cancer cells, these gradients 
(particularly Na+) are used by a variety of downstream transporters that perform other functions 
vital for viability including pH regulation via sodium-proton exchangers (e.g. NHE1) and 
sodium-bicarbonate cotransporters (e.g. NBCn1) (Liskova et al. 2019), glucose transport via 
sodium-dependent glucose transporters (e.g. SGLT1) and calcium homeostasis via sodium-
calcium exchangers (e.g. NCX1). Calcium homeostasis is also maintained by plasma 
membrane calcium-ATPases (e.g. PMCA1) (Déliot and Constantin 2015). As mentioned in a 
previous section, the ionic gradient of Ca2+ in mammalian cells is large, with normal 
intracellular Ca2+ concentration in the range of 100 nM and the extracellular concentration 
around 2 mM (Clapham 2007).  
Cells are generally more negative on the cytoplasmic side of the membrane, due to the presence 
of acidic aspartate and glutamate amino acid residues and negatively-charged membrane 
phospholipids including phosphatidylserine (PS) and phosphatidylinositol 4,5-bisphosphate 
(PIP2) (Call, Goyette, and Gaus 2017). Whilst the cell itself is electrically neutral, there does 
exist charge separation across the plasma membrane. In physical terms, VM is formed from the 
electrochemical gradients of ions at their physiological concentrations, each of which is 










Where Eion is the equilibrium potential of the ion, R is the gas constant, T is the absolute 
temperature, z is the valence of the ion and F is Faraday’s constant. Eion is also the VM at which 
there is no net flux of that ion across the membrane. In addition to these physical characteristics, 
VM is also dependent on the permeability of the cell to each ionic species, which is described 








𝑝𝐾[𝐾]𝑂 + 𝑝𝑁𝑎[𝑁𝑎]𝑂 + 𝑝𝐶𝑙[𝐶𝑙]𝑂
𝑝𝐾[𝐾]𝐼 + 𝑝𝑁𝑎[𝑁𝑎]𝐼 + 𝑝𝐶𝑙[𝐶𝑙]𝐼
) 
Where p is the permeability of the plasma membrane to the ionic species. In most mammalian 
cells, VM is negative, which is a result of a higher permeability to K
+ ions, which are more 
concentrated inside of the cell. The Goldman-Hodgkin-Katz equation does not account for the 
contribution of Ca2+ to VM. This is because free intracellular Ca
2+ is kept low (100 nM) and 












The VM of cancer cells is usually more depolarised (positive) than that of non-transformed 
cells. This is partly due to an increase in expression of Na+ channels and an increase in Na+ 
permeability (M. Yang and Brackenbury 2013). VM is also a contributor to cancer progression 
as depolarisation is able to induce a metastatic cell phenotype in vivo (Lobikin et al. 2012).  
1.6.1 Electrophysiology 
 
Electrophysiology is the technique of measuring electrical signals (current or voltage) from 
biological tissues using electrodes (most often Ag-Cl electrodes). Pioneering works in the 
1950’s headed by Alan Hodgkin and Andrew Huxley showed using squid giant axons that 
Figure 6. Simplified equivalent circuit diagram for a cell. Membrane potential VM is formed from the sum of the 
equilibrium potentials EX of the ions found in highest physiological concentration in parallel with the membrane 
capacitance CM. In normal cells, conductance to K+ (GK) is usually the highest and VM approaches EK. In cancer cells 





nerve fibres used changes in voltage to send signals via action potentials. They also observed 
that the different phases of the action potential were a result of currents carried by Na+ and K+ 
ions (Hodgkin and Huxley 1952). One early problem that Hodgkin and Huxley faced was that 
when trying to record current at different voltages, certain values of voltage (at the action 
potential threshold voltage) triggered sudden, unintended changes in VM that hindered accurate 
measurement of membrane current. This led them to develop the voltage clamp system, in 
which VM is held at some constant value (VC) and the current (that which is ‘injected’ by a 
current passing electrode) required to maintain VC  is equal in magnitude and opposite in sign 
to that passing through the cell membrane. Using this system with solutions of Na+ or K+ at 
different concentrations allowed them to evaluate how the conductance of each ion changes at 
different voltages and determine which phase of the action potential each contributes to. 
Hodgkin and Huxley hypothesised that these currents were carried by membrane proteins 
called ion channels, however it was not until the development of the patch clamp technique 
(figure 7) that their existence could be confirmed (NobelPrize.org 2021). Patch clamp 
electrophysiology was first developed by Erwin Neher and Bert Sakmann in the mid-1970s 
(Neher and Sakmann 1976) at the Max Plank institute in Göttingen, Germany. The technique 
involves applying a glass microelectrode with a tip a few micrometres in diameter to the cell 
in order to electrically isolate a small patch of cell membrane, which reduces extraneous noise 
and allows for measurement of single-channel currents. Whilst Hodgkin and Huxley used a 3-
electrode system, more modern electrophysiological systems use a two-electrode system – one 
reference electrode in the extracellular solution and one recording electrode which using an 
array of differential amplifiers, is able to both measure membrane voltage and pass current, 
switching between both modes at high frequency. After several years of developing the 
technique, Neher and Sakmann discovered that the main source of noise in this technique 
resulted from leak between the pipette and the cell membrane (‘access resistance’ – RA). They 
were able to circumvent this problem by using light pressure applied within the pipette to form 
a ‘gigaseal’, which results in partial capture of the cell membrane by the end of the pipette and 
RA in the GΩ range – a requirement for measurement of the tiny currents produced by ion flux 
through cell membranes. Several other seal configurations are possible (summarised in figure 
7B), one of which allows for measurement of ‘whole-cell’ current (i.e. the current formed from 
the sum of all conductances within the cell). 
In patch clamp experiments, the composition of the extracellular solution and the pipette 
solution can be varied, to maximise signals from the ion channels of interest and reduce noise 
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from other channels. Different components often used alongside the traditional extracellular 
solution (i.e. HEPES-buffered physiological salt solution) include Ba2+, which is a Ca2+ 
analogue that has the advantages of producing a higher current amplitude through L-type CaV 
than Ca2+ (Guia et al. 2001) and is also more specific to Ca2+ channels – it is almost entirely 
impermeant to Na+ channels (Bean 1992). Ba2+ may also block K+ channels by binding to 
residues in the selectivity filter of K+ channels (Jiang and Mackinnon 2000). Compounds used 
in the pipette solution when measuring current carried by Ca2+ channels include caesium (Cs+) 
and tetraethylammonium chloride (TEA) – both of which are non-specific blockers of K+ 
channels (B. Owen, Reddy, and Grover 2017). Another important consideration in 
electrophysiology is the osmolarity of the solutions – large differences can cause cell swelling 
or shrinkage that can affect membrane stability. Certain ion channels (e.g. the volume regulated 
anion channel VRAC) are also activated in hypo-osmotic conditions (Liu and Stauber 2019).    
Whilst the single channel technique is useful in cells with high expression of an ion channel 
(e.g. neurons or transfected cells), the most common patch clamp experimental setup for 
measuring voltage-gated ion channels in traditionally non-excitable cells uses the ‘whole cell’ 
pipette configuration in which the pipette solution becomes continuous with the cell cytoplasm.  
The most common protocol used when measuring current through CaV is the voltage step 
protocol. Cells are first held at hyperpolarised (negative) potential and then square voltage 
pulses of increasing magnitude with a duration of tens to hundreds of milliseconds are applied 
and sweeps of concomitant current are recorded. Data from this protocol can then be used to 







Figure 7. A) Simplified diagram of the patch clamp electrophysiology setup (not to scale). A sharp electrode is 
brought to the cell membrane and suction is applied to pinch the membrane. The voltage is measured via 
comparison of the recording electrode and the reference electrode. The headstage interfaces with the amplifier, 
which interfaces with a digitizer, that sends the information to the computer and receives information on command 





1.7 Main aim and objectives 
 
The overall aim of this work is to Determine whether DHP antagonism of CaL has any effect 
on the malignant behaviour of ovarian cancer cells, or whether these compounds possess any 
cytotoxic effects that could be exploited for clinical use. The specific experimental objectives 
of the work are:  
1. Determine whether CaL are expressed in cells from various biological sources (tumours, 
ascitic cells and cell lines) by assessing specific protein and mRNA levels. This 
knowledge is important because it can then be used to inform the direction of the 
research and may provide information as to which stage or subtype of disease these 
channels could be important and also which cell lines are amenable to specific 
experiments.  
2. Determine whether pharmacologic inhibition of CaL with DHP has any effect on 
malignant properties of cells, including cell viability and migratory capacity or whether 
DHP have any apoptotic effect. This is important to determine the possible beneficial 
effects of DHP use on patients with ovarian cancer and may also direct further research 
into the role of these channels.  
3. Determine whether CaL are functional in the OC cells in which they are expressed. This 
will facilitate understanding of the molecular biology behind possible anti-cancer 
effects and provide further evidence of the importance of CaL in this disease. 
This work is completely novel, as a search of the literature returns no other research that has 
assessed the expression or localisation of CaV in ovarian MAF derived cells.  There are also 
very few published works relating function of CaV to malignant characteristics in ovarian 
cancer. However, although the experiments performed may be unique, this research does fit 
into a broader general theme of contemporary research which places a greater emphasis on 














2. Materials and Methods 
2.1 Cell culture methods 
2.1.1 Cell lines 
 
Maintenance of cell lines and primary cells was facilitated by incubation in cell culture 
incubators (Sanyo) set at 37oC and with a constant air/5% CO2 supply. 
The SKOV-3 OC ovarian adenocarcinoma cell line (ATCC code: HTB-77, passage number 
P32 – P39) were a gift from Professor Heidi Sowter (Nottingham Trent University). These cells 
are in widespread use in ovarian cancer research and were originally derived from the ascites 
fluid of a 64-year-old patient.  
The OVCAR-3 ovarian adenocarcinoma cell line (ATCC code: HTB-161, passage numbers 
19-24) were purchased from ATCC. These cells were derived from the malignant ascites of a 
60-year-old patient after combination chemotherapy with cyclophosphamide, Adriamycin and 
cisplatin (Hamilton et al. 1983).   
Figure 8. Scheme for the present research, to determine whether CaV antagonism is a viable 
treatment option in ovarian cancer 
 
Stage 1: Assess CaL channel expression in different 
biological sources of ovarian cancer tissue 
Stage 2: Use data from stage 1 to choose a sample 
source with high CaL expression for further study, 
analysing expression and subcellular localisation
Stage 3: Analyse the effect of CaL antagonism on 
malignant behaviour of ovarian cancer cells




The OVCAR-8 (passage number P49 – P54, respectively) is a widely-used OC cell line (NIH 
2015) of unknown origin, although these cell do form tumors with HGSOC histology when 
implanted into nude mice (Mitra et al. 2015). 
Both the SKOV-3 and OVCAR-8 cell lines were grown in tissue culture treated T-75 flasks 
(Falcon) cultured in RPMI + 10% foetal bovine serum (FBS) + 1% penicillin streptomycin 
(p/s) and passaged at 80% confluency. The OVCAR-3 were grown in the same conditions as 
the SKOV-3 and OVCAR-8, except that they were grown in RPMI + 20% FBS. 
The SH-SY5Y neuroblastoma cell line (ATCC code: CRL-2266, passage number 25-27) were 
purchased from ATCC. These cells were derived from the bone marrow of a 4-year-old female 
patient. These cells were used as a positive control for CaV current, as they display functional 
CaV channels that can be measured using electrophysiology (Toselli et al. 1991). These cells 
were cultured in 1:1 Dulbecco’s modified eagle medium (DMEM)/F12 + 10% FBS and 
passaged at 75% confluency. 
2.1.2 Formation of single spheroids 
 
Formation of SKOV-3 and OVCAR-8 single spheroids was achieved using a 
polyhydroxyethylmethacrylate (polyHEMA, Thermo) coated 96-well plate. First, a solution of 
20 mg/mL polyHEMA in 100% EtOH was made and left to stir at 50oC overnight. The next 
day the polyHEMA solution was sterilised by passing through a 0.2 µm filter and added at a 
volume of 30 μL to the wells of a round-bottom 96-well plate and left in a flow hood overnight 
to set. For spheroid formation, each well of the polyHEMA-coated 96-well plate was seeded 
with 5000 cells and plates with covers centrifuged at 2000 x g for 5 min. 
2.1.3 Formation of bulk spheroids 
 
Bulk spheroid formation was achieved using a polyHEMA-coated T75 flask. The solution of 
polyHEMA was prepared as in section 2.1.2, and the polyHEMA solution was then added to 
the flask at a volume of 15 mL and left in a flow hood overnight to set. For spheroid 
formation, 106 cells were seeded onto the flask and left for 2-3 days in growth media until 
spheroids had formed. 
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2.2 Isolation of cells from malignant ascitic fluid and culture method 
2.2.1 Isolation of malignant ascites derived cells 
 
Bulk ascitic fluid (usually between 500 mL and 2 L) from ovarian cancer patients undergoing 
paracentesis was collected into containers. 50 mL of this fluid was then aliquoted into 50 mL 
Falcon tubes, centrifuged at 200 x g for 5 min at room temperature (RT) and the resultant 
supernatant collected and stored at -80oC. The cell pellet was then resuspended in 3 mL warm 
Hank’s buffered saline solution (HBSS). A gradient of Percol was made by initially diluting a 
100% Percol solution in PBS, creating a 50% and 60% solution. 7 mL of 60% then 7 mL of 
50% was then carefully added to a Pyrex tube, the 3 mL cell solution was carefully added on 
top and the tube was centrifuged at 200 x g at 4oC for 20 min. The layer of cells which remained 
at the 50:60 interface (tumour cells, fibroblasts, leucocytes, endothelial cells) was then taken 
into 10 mL warm HBSS with a Pasteur pipette and centrifuged for 5 min at RT. The cells were 
then resuspended in 90% FBS + 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen 
until required for experiments. 
2.2.2 Culture of malignant ascitic fluid derived cells 
 
Malignant ascitic fluid derived cells were cultured in complete growth media consisting of 1:1 
Medium 199, Medium 105 + 20% FBS + 1% p/s. All experiments were performed within 24 
hours of thawing of cells from liquid nitrogen. 
2.3 Wound-healing assay and invasion assay methods 
2.3.1 Wound-healing assay 
 
Wound healing assays were performed in 24-well plates on well coated in 5 μg/cm2 bovine 
plasma fibronectin (Thermo). To prevent cell division during the experiment, when cells were 
~50% confluent they were serum-starved by replacing culture media with RPMI +2% FBS + 
1% p/s and the experiment performed the following day. For the experiment, a single scratch 
was made in each well with a P200 pipette tip and the cells were returned to the incubator for 
30 min to allow settling of wound edges before drug treatments were applied. During data 
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collection a transparent Perspex grid was attached to the plate to allow photographs of the same 
region of each well to be photographed at each time point. 
2.3.2 Invasion assay 
 
Invasion assays were performed using 8 μm pore size transwell inserts (Corning) in either the 
6-well or 24-well format. Inserts were first coated with either 45 μL (24-well) or 100 μL (6-
well) of Geltrex (Gibco) basement membrane extract derived from Engelbreth-Holm-Swarm 
(EHS) mouse sarcoma cells. The well bottoms were filled with 0.4 mL of 20% ascitic fluid 
from a confirmed ovarian cancer patient in base medium (either RPMI or 199/105 for cell lines 
or MAF derived cells, respectively) and cells were plated on the top of the inserts at 4*104 
cells/per insert in 0.1 mL of corresponding complete growth medium. After drug treatments, 
the plates were then left in the incubator for 24 hr before staining. To stain, inserts were washed 
in PBS then fixed in fresh 4% paraformaldehyde (PFA), washed again then permeabilized with 
100% methanol and washed again then incubated in 0.5% crystal violet. Images of invasive 
cells were then taken at 40X magnification and the data analysed using ImageJ. Extent of 
invasion in different treatment conditions was quantified by counting the number of invasive 
cells and comparing to vehicle-treated controls (1% EtOH). 
2.4 Reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
 
Total RNA was purified from lysed cells using the RNeasy Mini Kit (Qiagen) per 
manufacturer’s instructions. A nanodrop spectrophotometer was used to measure the 
concentration of RNA as well as the ratios of absorbance at 260/280 and 230/280 - measures 
of protein and phenol contamination, respectively. RNA was then diluted to 120 ng/μL before 
being reversed transcribed into cDNA using random primers (Applied Biosystems). RT-qPCR 
experiments were performed in a clear-bottom 96-well plate using the TaqMan primers 
(Thermo): CACNA1C (Hs00167681_m1), CACNA1D (Hs00167753_m1), CACNA1S 
(Hs00163885_m1), EPCAM (Hs00901885_m1), ACTA2 (Hs00426835_g1) and reference gene 
HPRT (Mm03024075_m1) – confirmed in a separate study in our laboratory to have the least 
variable Cq value (from 7 potential genes) between OC tumours and normal ovaries. Data was 
collected using CFX manager software (Bio-Rad). Relative expression (RE) was calculated 
via: RE = 2ReferenceCq-TargetCq. Primer replication efficiency was calculated via: E = -1+10(-1\-slope).  
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2.5 Western blotting 
2.5.1 Sample preparation 
 
Cells or tissues were first appropriately homogenised for protein purification. For tissues, 5 mg 
of tissue was first cut up into pieces with a scalpel. These were then added to a homogenization 
tube with 10 mL of ice cold NP40 buffer + protease inhibitor cocktail (Pierce) and 
homogenized with an electric homogenizer on ice. For cell lines, cells growing in flasks were 
first washed with warm HBSS before adding 1 mL cold NP40 buffer + protease inhibitor 
cocktail. Tissue/cell homogenates were then collected into a 1.5 mL Eppendorf tube using a 
cell scraper and left for 30 min at 4oC with agitation. Homogenates were then passed 25X 
through a 21-gauge hypodermic needle and then sonicated on ice for 15 min. Homogenates 
were then centrifuged at 1400 x g for 5 min at 4oC to remove large particles such as nuclei and 
mitochondria. The supernatant was collected and centrifuged at 2.4*104 x g for 1 hr at 4oC to 
obtain a partial membrane purification, found in the supernatant. 
Human myometrium and ovarian tumour tissues were cut with a scalpel to an appropriate 
weight and homogenised in NP40 buffer + protease inhibitor cocktail on ice with an electric 
homogeniser. Homogenates were then subject to the same centrifugation regime as above. 
Measurement of protein concentration was achieved using a bicinchoninic acid assay (BCA). 
CuSO4 was mixed with Bicinchoninic acid at a ratio of 1:50 and added to a 96-well plate at 90 
μL/well. A standard curve of protein concentrations ranging between 4 and 0.25 mg/mL was 
created using bovine serum albumin (BSA) and both standards and unknowns were added to 
the plate at a volume of 10 μL. After 30 min agitation at 37oC, the absorbance at 562 nm was 
read using a plate reader (Thermo) and the concentration of the unknown samples extrapolated 
from the absorbance from the standards. 
2.5.2 SDS-PAGE, membrane transfer and western blotting 
  
Homogenates were resuspended in Laemelli buffer with 5% 2-mercaptoethanol, vortexed for 
1 minute and heated at 70oC for 10 minutes. Protein electrophoresis was then performed using 
Bio-Rad Mini-Protean TGX precast 10% polyacrylamide gels in Tris/Glycine buffer. Gels 
were run at a constant 40 mA for 50 min. Transfer of protein to the nitrocellulose membrane 
(pre-wetted with Towbin buffer) was facilitated by electrophoresis at a constant 100V for 2 
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hours at 4oC in Towbin buffer containing 10% methanol. After protein transfer, membranes 
were briefly washed with dH2O before being stained with Ponceau red, to visualise the 
proteins. After washing, membranes were incubated overnight in primary antibody – either 
1:1000 Ms anti-CaV1.2 (ab84814) or 1:1000 Rb anti-CaV1.3 (ab191038), both diluted in 3% 
Marvel. The following day, membranes were washed and then incubated with secondary 
antibody diluted 1:1000 in 3% Marvel - either AP-conjugated Gt anti-Rb (D0487) or AP-
conjugated Gt anti-Ms (D0314) and then washed. Membranes were then incubated in 15 mL 
immune-star substrate for 10 min before imaging on a chemi-doc. Qualitative assessment of 




Biopsies of patients with ovarian carcinoma were analysed via immunohistochemistry (IHC). 
Historic samples were obtained from the Royal Derby hospital in accordance with all relevant 
ethical authorities. The samples were taken from patients between the ages of 26 and 89 years 
of age (median = 62.0 years) and included the following subtypes of ovarian carcinoma (serous, 
mucinous and endometroid). 
Formalin-fixed paraffin-embedded (FFPE) tumour samples were sectioned at a thickness of 10 
μm and mounted to the slides using heated dH2O. The paraffin was then dissolved using 
histoclear and the samples rehydrated via 2-min incubations in decreasing concentrations of 
ethanol (90% and 70%). Samples were then incubated in 0.3% H2O2 for 20 min, to inhibit 
endogenous peroxidase activity and reduce subsequent background staining. Antigen exposure 
was achieved by incubating samples in 100 mM sodium citrate buffer (pH = 6) and 
microwaving on full power for 10 minutes, followed by further heating at low power for 10 
minutes. After washing in PBS, samples were then incubated for 30 min at room temperature 
in 150 μL of blocking buffer: 0.2% goat serum in PBS (Vectastain). After removal of blocking 
buffer, samples were then incubated for 1 hour at room temperature in 150 μL primary antibody 
– either Ms anti-CaV1.2 (ab84814) or Rb anti-CaV1.3 (ab191038). After removal of primary 
antibody, samples were incubated for 30 min at room temperature in 100 μL of secondary 
antibody: biotinylated goat anti-rabbit IgG (Vectastain). After washing in PBS, samples were 
then incubated for 45 min at room temperature in 100 μL streptavidin-conjugated horseradish 
peroxidase (HRP) reagent (Vectastain). After washing in PBS, samples were then incubated 
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for 5 min at room temperature in 100 μL of the colourimetric HRP substrate 3,3’-
Diaminobenzidine (Thermo), which produces a brownish stain at the area of the tissue that 
expresses the target antigen. Subsequent imaging of stained sections was performed with an 
inverted light microscope with attached DS-Ri1 camera (Nikon). 
2.7 Immunofluorescent imaging of ascites-derived cells using wide-field microscopy 
 
Ascites-derived cells were resuspended in CGM then plated onto 13 mm #1.5 glass coverslips 
coated with 5 μg/cm2 collagen-1 (Thermo) and left in the cell culture incubator overnight in a 
24-well plate. The following day, cells were washed 3X with 1 mL warm PBS before being 
fixed in 250 μL cold paraformaldehyde (PFA). Fixed cells were then washed 2X with 1 mL 
PBS at RT for 5 min with gentle shaking. Permeabilisation was then achieved through 
incubation for 5 min at RT with 500 μL 0.5% igepal/PBS before the cells were again washed 
2X in 1 mL PBS for 5 min with gentle shaking. Blocking of off-target antibody binding sites 
was then achieved via incubation of cells for 45 min at RT with 500 μL 1% BSA/2.5 % glycine 
solution. Primary antibody against CaV1.2 (Abcam ab84814) and EpCAM (Abcam ab71916) 
were diluted to their required concentration in separate bijous using 10 mg/mL BSA in PBST 
and added to the cells at 200 μL/well and cells were then incubated for 1 hour at RT with gentle 
shaking. Fluorophore-conjugated secondary antibodies raised against IgG subtypes (anti-
mouse 647: ab150115 and anti-rabbit 488: ab150077) used as primary antibodies were then 
diluted to their required concentration in 10 mg/mL BSA in PBST and added to the cells at 200 
μL/well and incubated for 1 hour at RT with gentle shaking in the dark. Cells were then washed 
3X with 1 mL PBS for 5 min with gentle shaking. Coverslips were then mounted onto slides 
using DAPI-containing mounting medium (Vector Labs) and left to dry for 30 min. Slides were 
then left at 4oC overnight before imaging the following day using a DeltaVision Elite widefield 
fluorescent microscope controlled with Zen software (Zeiss). 
Colocalization analysis was performed using the Coloc 2 plugin of Fiji. Using the region of 
interest manager, three individual cells or spheroids were first selected per image from the 
bright field image. Using the automatic intensity threshold function, Pearson’s correlation (r) 
values were then calculated using channels for DAPI (nuclear staining) and Alexa 647 
(CaV1.2). Hypothesis testing was then performed on the Pearson’s r values using Coste’s test, 
which measures the correlation between the signal from the two fluorophores on 100 images 
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from the ROI with randomized pixels and then compares the resulting r values to those obtained 
in the experiment. In Coste’s test, a P value of ≥0.95 is considered significant. 
2.8 Flow cytometry 
2.8.1 Annexin-V apoptosis assay 
 
SKOV-3 or OVCAR-8 cells were resuspended in CGM and seeded into T25 flasks at 
3*105 cells/flask and then either treated with specific drug concentrations or left as controls 
and then left to grow for 48 hours. On the day of the experiment, cells were trypsinsed, washed 
in warm PBS and then resuspended in annexin-binding buffer before being aliquoted into 1.5 
mL Eppendorf tubes at 100 μL. All aliquots except the controls were then incubated with 1 μL 
PI and 5 μL 488-conjugated annexin-V and incubated at RT until measurement. The flow 
cytometry experiment was performed using an FC500 flow cytometer (Beckmann-Coulter). 
Analysis of flow cytometry data was performed using Kaluza software (Beckman). 
2.8.2 Antibody panel using ascites-derived cells 
 
Ascites-derived cells were resuspended in 1 mL warm PBS and aliquoted into 1.5 mL 
Eppendorf tubes. Then, 1 μL of NIR zombie viability dye (BioLegend 423105) was added to 
the cells and they were incubated for 15 min at RT in the dark. After 15 min, 500 μL blocking 
buffer (1% BSA in PBS) was added to each tube and the whole volume was aliquoted into a 
new tube before being centrifuged at 600 x g for 2 min. Cells were then resuspended in 100 μL 
solution containing the following fluorophore-conjugated primary antibodies at dilutions 
recommended by the manufacturers: Alexa Fluor 488 anti-CD45 (BioLegend 368535) and 
Phycoerythrin (PE) anti-EpCAM (Cell signalling #8995S). The cells were then incubated for 
20 min at RT in the dark. Cells were then centrifuged at 600 x g for 2 min and resuspended in 
400 μL fixative (0.5% PFA) and incubated at RT for 20 min in the dark. Cells were then 
centrifuged again at 600 x g for 2 min and resuspended in a membrane-permeabilising solution 
(blocking buffer + 0.5% igepal in PBS) containing primary antibody against CaV1.2 (Abcam 
ab84814, intracellular epitope) and incubated for 20 min at RT in the dark. The CaV1.2 primary 
antibody was conjugated to Cy5 using a Cy5 conjugation kit (Abcam ab188288) prior to use. 
Cells were then centrifuged again at 600 x g for 2 min, resuspended in fixative and kept on ice 
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in the dark. The flow cytometry experiment was performed on the same day using an Astrios 
EQ flow cytometer (Beckmann-Coulter). 
Analysis of flow cytometry data was performed using Kaluza (Beckman). Spectral overlap 
between fluorophores was compensated for using single stained controls (sample 13). In order 
to identify and remove leucocytes from the data, different cell populations were identified in 
the CD45 single stained aliquot using forward scatter (FSC) vs. side scatter (SSC). These 
populations were then subject to doublet discrimination using FSC-Height vs. FSC-area, gated 
on viability using the zombie dye and the resulting live cells split into CD45+/CD45- 
populations. A population of small lymphocytes was found and included as a gate on the FSC 
vs. SSC graph of all experimental samples.  
The second FSC vs. SSC gate included larger cells, which were subject to the same process of 
doublet discrimination, live cell gating and separation into CD45+/CD45- populations. Dot 
plots of CaV1.2 area vs. EpCAM area were then created from the resultant CD45
- population 
and quadrant gates applied to discriminate the +/- status of the cells. 
2.9 Electrophysiology 
 
Inward Ca2+ currents were measured using the whole-cell patch clamp technique with a 
headstage attached to a 700B amplifier (Axon Instruments). Sharp electrodes (outside diameter 
= 1.2 mm, inside diameter = 0.69 mm) were pulled from borosilicate glass capillaries (Sutter 
instruments BF120-69-7.5) using a glass puller (Sutter instruments) to give a typical bath 
resistance of 2-5 MΩ. The electrodes were back filled with a solution consisting of (mM): 60 
CsCl, 60 CsOH, 60 TEA-Cl, 2 MgCl2, 10 HEPES, 10 EGTA, pH = 7.35. The bath solution 
consisted of (mM): 130 NaCl, 5 KCl, 10 BaCl2, 10 HEPES, 15 mannitol, 10 mM glucose, pH 
= 7.35. All cells were washed 3 times in extracellular solution immediately prior to the 
experiment. 30 mm NUNC dishes (Thermo) were used for patch clamp experiments and were 
coated with 5 μg/cm2 of either poly-D-lysine (Thermo) or collagen-1 (Thermo) prior to plating 
with ovarian cancer cell lines or primary cells, respectively. 
After achieving a seal resistance ≥3 GΩ, cells were held at a negative potential of -60 mV for 
one minute. Positive pressure was then released from the airline and if breaking in was 
successful, capacitive transients were normalised using pCLAMP 11 software (Molecular 
Devices). Cells were then held at -80 mV for 30 sec. Square voltage pulses of 200 msec and 
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+10 mV increments were then applied from -60 mV to +60 mV. Recording of whole-cell 
inward currents was performed using pCLAMP and analysed using clampfit (Molecular 
Devices). 
2.10      Immunoprecipitation 
 
2.10.1 Cell culture and lysate preparation 
 
Four groups of cell monolayers were cultured: OVCAR-8 and SKOV-3 cells +/- 5 µg/cm2 
fibronectin were seeded in T-75s at 106 cells/flask and grown until near confluence. Samples 
were prepared for western blotting via the same procedure outlined in section 2.6.1 ‘sample 
preparation’. 
2.10.2 Coating of magnetic beads with capture antibody 
 
Four aliquots of Protein G-linked magnetic beads (Dynabeads, Thermo) were prepared by 
transferring 50 µL of bead slurry to 0.5 mL Eppendorf tubes. The tubes were then place on a 
magnet to separate the beads from the solution, the solutions were discarded, and the beads 
were then resuspended in 200 µL of 0.02% tween in PBS. 10 µg of CaV1.2 mouse capture 
antibody (ab84814) was then added to each Eppendorf tube and the solutions were gently 
pipetted, then incubated with rotation at RT for 10 min. The Eppendorf tubes were again placed 
on the magnet, the solution removed, and the beads were then washed in 0.02% tween in PBS.  
2.10.3 Protein capture, immunoprecipitation, and preparation for western blotting 
 
The 0.02% tween in PBS solution was then removed using the magnet, the beads resuspended 
in 400 µL cell lysate (one condition per Eppendorf tube) and the tubes incubated with rotation 
at RT for 10 min. The magnet was then used to separate the beads the, solution removed and 
stored on ice (AbAg-) and the beads-containing Eppendorf (AbAg+) tube kept on ice. For 
western blotting, beads were then resuspended in 60 µL Laemelli buffer + 2-mercaptoethanol 
(2-ME). 30 µL AbAg- solutions were added 1:1 with Laemelli buffer + 2-ME. Neat cell lysate 
solutions were diluted ¼ in NP-40 then 30 µL was added 1:1 with Laemelli + 2-
mercaptoethanol. All solutions were then vortexed for 1 min and heated at 70oC for 15 min. 
Blotting was performed as in section 2.6.2 ‘SDS PAGE, membrane transfer and western 
blotting’ except the primary antibody used was Rb anti-integrin α5 (ab150361) used at 1:1000. 
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2.11  Fluorescence measurement of Ca2+ fluxes in cancer cells using Fluo4 
 
Cancer cell lines SH-SY5Y and OVCAR-8 were grown for 3 days in T-75 flasks before the 
experiment, cultured in their respective CGM detailed in section 2.1.1. All cell cultureware 
facilitating SH-SY5Y cell growth were coated with 10 µg/cm2 poly-D-lysine and all 
cultureware facilitating OVCAR-8 cell growth were coated with 5 µg/cm2 poly-D-lysine. The 
day before the experiment, cells from confluent flasks were trypsinised, transferred to a 96 well 
plate (8000 cells/well) and allowed to grow in the cell culture incubator overnight.  
On the day of the experiment, Fluo4 loading media was made by first resuspending Fluo4-AM 
powder (Thermo F14201): three vials with 10 µL DMSO (Fluo4 concentration 4.56 mM). All 
10 µL was then added to a 10 mL aliquot of either SH-SY5Y CGM (minus serum, +1% BSA, 
+2.5 µM DMSO) or two 10 mL aliquots of OC cell line CGM (minus serum, +1% BSA, +2.5 
µM DMSO) to give to give three aliquots of loading media  
Cells were then washed with 0.2 mL warm HBSS before incubating for 15 min in 0.2 mL of 
their respective loading media at RT. After 15 min, to allow time for intracellular de-
esterification of Fluo4-AM molecules to their cell impermeable form, cells were washed again 
with warm HBSS and then incubated in CGM (minus serum, +1% BSA) for 20 min at RT. 
After 20 min, the CGM was replaced with measurement media: HBSS +1 mM Ca2+. Fluo4-
loaded cells were then subject to pharmacological treatment with the CaV agonist Bay K8644 
(Sigma, B112-5MG) with one of three different conditions: 1) vehicle control (2.5% EtOH), 
2) 2 µM Bay K844 or 3) 10 µM Bay K8644). 
Immediately after treatment, measurement of Fluo4 fluorescence signal (excitation wavelength 
494 nm, emission wavelength 506 nm) was conducted using a Varioskan LUX plate reader 
(Thermo) set to perform the measurement for 0.10 sec with a lag time that facilitated one 
measurements per minute (total duration 10 min). Statistical significance was analysed with 
Graphpad Prism, using a two-way repeated measures ANOVA with multiple comparisons 
comparing each column mean to that of the vehicle control.  
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3. Expression of L-type CaV in ovarian cancer cells from different biological sources 
3.1 Introduction 
 
There is little data in current literature regarding protein expression of CaL in ovarian cancer. 
A search of the Human Protein Atlas (HPA) reveals that while only 1/9 ovarian tumours stain 
positive for CaV1.1 (an endometroid tumour) and 2/12 ovarian tumours stained positive for 
CaV1.2 (one mucinous and one endometroid tumour), all 11/11 ovarian tumour samples 
composed of serous, mucinous and endometroid stained positive for CaV1.3.  
Results of DNA microarray experiments by other groups are contradictory, with some groups 
showing a general under-expression of CaL mRNA in tumours from different cancers (Phan et 
al. 2017) and others showing the opposite (C. Y. Wang et al. 2015) – although neither of these 
show high magnitude changes. Data regarding CaL expression in other OC samples sources 
such as metastases and ascitic cells is even more sparse. 
In order to determine whether L-type CaV are a valid subject of study in OC in the present 
work, large publicly-available datasets of DNA microarray data from serous ovarian tumours 
made available by the cancer genome atlas (TCGA) were first searched. Figures that can be 
generated from TCGA data display the proportion of serous ovarian tumors with under and 
over expression of a mRNA as a bar chart (blue and red bars, respectively), and also present 
survival as a Kaplan-Meier plot – which the proportion of all patients surviving as a function 
of time after initial diagnosis (blue curve), as well patient survival in the subset with high 
CACNA1C expression (red curve). This data was then used to determine if there are any specific 
mRNA expression trends for the different pore-forming CaV α-subunit isoforms that could 
inform the direction of the research. Other studies have shown that different α-subunit isoforms 
can be either upregulated or downregulated depending on the type of cancer (Gong et al. 2013). 
To further probe the possible contribution of L-type α-subunits to a clinical outcome, matching 
overall survival data was also analysed. 
It is also important to determine at which stage of disease or in which anatomical location L-
type α-subunit expression may be altered. Thus, quantification of expression of these mRNAs 
in normal ovaries and solid tumour as well as malignant ascitic fluid (MAF) derived cells and 
OC cell lines was performed using RT-qPCR. 
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All ascites-derived samples were also subject to RT-qPCR using probes for the carcinoma cell 
marker EpCAM (Keller, Werner, and Pantel 2019) and α smooth muscle actin (α-SMA, an 
actin protein specific to contractile cells). Expression of these genes was normalised using the 
reference gene Cq and the relative expression used as a crude measure of the inter-sample 
difference in the amount of cancer cells and cancer associated fibroblasts (CAFs), respectively. 
As CAF also express CaV (Sadras et al. 2020) it is important to measure their burden to 
normalize CaV expression levels in these samples. 
In addition, expression of CaV1.2 and CaV1.3 protein in solid tumours (n = 40: 32 serous; 3 
mucinous; and 5 endometroid) was determined using immunohistochemistry (IHC) and the 
levels of these proteins in ovarian cancer cell lines was also determined using western blotting. 
Data from the Human Protein Atlas (HPA) suggest that the CaV1.3 subunit is the more widely 
expressed subunit in ovarian tumours, with expression in serous, mucinous and endometroid 
OC (The Human Protein Atlas 2020), whereas CaV1.2 expression seems to be restricted to a 
small number of mucinous and endometroid samples (J. Y. Zhang et al. 2019).  
The objective of the current chapter is to determine whether CaL display expression in different 
sample sources from patients with ovarian cancer in order to determine at which stage of the 
disease these channels start functioning. 
3.2 Results 
 
3.2.1 Expression of CaV channels in ovarian tumour samples 
3.2.1.1 CaL mRNA alteration and survival trends in public datasets 
 
Serous ovarian tumour gene microarray datasets from TCGA were first analysed and alteration 
frequency and survival for different CaL genes compared. 
Data from TCGA revealed that CACNA1C and CACNA1D mRNA were over-expressed in 
around 5% of patient samples (figures 9A-B, 10A-B and 11A-B). CACNA1S was altered in up 
to 5% of patients, although half of these were under-expression figures 9C, 10C and 11C). 
Analysis of TCGA survival data showed CACNA1C to be the only over-expressed gene 
associated with significantly lower overall survival in all data sets (figures 9A, 10A and 11A).  
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CaV mRNA expression may vary between tissue or cell type. For example, according to the 
HPA, CACNA1D mRNA displays low expression in normal ovaries but high expression in 
fallopian tube tissue. One of the main caveats of using TCGA to direct further research is that 
all of these data are from serous ovarian carcinoma, meaning that possible alterations of CaL 
α-subunit gene expression in other subtypes of ovarian carcinoma with different tissues of 
origin such as endometroid (Kurman 2013) may be missed. However, as  mentioned in the 
introduction, serous OC does account for 75% of cases – making it a good starting point for 


















Figure 9. TCGA ‘Firehose’ microarray dataset. Percentage of serous ovarian cystadenocarcinoma patients (n = 602) 
with overexpression (pink bar) and underexpression (blue bar) of mRNA: A) CACNA1C, B) CACNA1D, C) CACNA1S 







































Figure 10. TCGA ‘Nature Agilent’ microarray dataset. Percentage of serous ovarian cystadenocarcinoma patients 
(n = 489) with overexpression (pink bar) and underexpression (blue bar) of mRNA: A) CACNA1C, B) CACNA1D, C) 

































3.2.1.2 CaL mRNA expression in stage 3 tumours and normal ovaries 
 
To validate the results seen in section 3.2.1.1, RT-qPCR with primers for CACNA1C and 
CACNA1D was performed on normal ovaries and stage 3 serous tumours. The data showed no 
significant difference in expression of these genes between the two groups (figure 12). This is 
consistent with data from TCGA and it is probable that an upregulation in ~5% of samples 
would be observed if the sample sizes were increased. 
Figure 11. TCGA ‘PanCancer Atlas’ microarray dataset. Percentage of serous ovarian cystadenocarcinoma 
patients (n = 585) with overexpression (pink bar) and underexpression (blue bar) of mRNA: A) CACNA1C, B) 

















Commented [LF1]: not corrected as per Randolph’s comment. 












3.2.1.3 CaL protein expression in FFPE ovarian tumours 
 
To determine the presence of CaV1.2 and CaV1.3 protein in FFPE tissues, IHC staining was 
performed. 
Staining in this experiment results from the sequential binding of primary 
antibody to target protein, followed by binding of horseradish peroxidase (HRP) conjugated 
secondary antibody to primary antibody. The colourigenic substrate 
diaminobenzidine (DAB) is then added and is converted into a localized brown stain by 
the HRP enzyme. 
CaV1.2 protein was not detected in any of the ovarian tumour samples subject to IHC 
staining (n = 40, figure 13). No serous tumours displayed expression CaV1.3 protein. However, 
staining for CaV1.3 was seen in one section from a mucinous tumour and one endometroid 







Figure 12. Relative expression of CACNA1C (n = 5) and CACNA1D mRNA (n = 3), calculated from the ratio of 
reference gene Cq and target gene Cq, where Cq is the PCR cycle at which significant fluorescence is measured 
from amplification of gene-specific probes). Data are from normal ovaries and stage 3 serous ovarian tumours. 
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3.2.2  Expression of CaV channels in malignant ascitic fluid derived cells 
3.2.2.1 CaL mRNA expression in ascites derived cells 
 
Samples of cDNA from MAF derived cells were subject to RT-qPCR to quantify expression 
of CaL α-subunit mRNA (figure 14). No appreciable expression of CACNA1S was detected in 
any sample. CACNA1C and CACNA1D displayed relatively low, uniform expression across 
the samples derived from patients with serous ovarian cancer (figure 14). However, when 
compared to the average expression in the serous ovarian cancer patients (samples 4, 8, 12 and 
13), expression of the same genes in the sample derived from a mucinous ovarian cancer 
(sample 10) were 6.2 times higher for CACNA1C and 9.4 times higher for CACNA1D. This 
increased expression was also evident after normalisation of CaV α-subunit mRNA expression 






Figure 13. Example images of IHC staining of ovarian tumour tissue for CaV1.2 and CaV1.3 in A) serous B) 
mucinous and C) endometroid. Magnification is 40X. Brown colour indicates positive staining. 






































3.2.2.2 EPCAM and ACTA2 expression in ascites derived cells 
 
In order to determine the burden of cancer cells and cancer-associated fibroblasts in MAF 
derived samples, RT-qPCR was performed using primers for EPCAM (EpCAM) and ACTA2 
(α-smooth muscle actin), respectively. Figures show the fold-difference in mRNA expression 
of the gene of interest relative to the expression of the reference gene (HPRT). These figures 
give an idea of how expression of these genes varies between the samples. 
EpCAM expression remained relatively stable across all 4 samples. ACTA2 expression was 
generally lower, which is expected as CAF make up a smaller fraction of the ascitic cellular 
burden (Q. Gao et al. 2019). The results from the α-SMA probe suggests that sample 12 had a 
higher proportion of CAF, which may also be responsible for the bias towards CACNA1C 












As cancer-associated fibroblasts also express CaL, the mRNA expression values for CaV1.2 and 
CaV1.3 obtained from the MAF derived cells were divided by their matching ACTA2 expression 
values, to normalise for differences in cancer-associated fibroblast expression (figure 16). 
Figure 14. RT-qPCR data from malignant ascites-derived cells. Log10 relative expression of CACNA1C and 
CACNA1D mRNA (calculated from the ratio of reference gene Cq and target gene Cq, where Cq is the PCR cycle 
at which significant fluorescence is measured from amplification of gene-specific probes). Data are mean +1 S.D. 
 
Figure 15. RT-qPCR data from malignant ascites-derived cells. Relative expression of ACTA2 and EPCAM mRNA 
calculated from the ratio of reference gene Cq and target gene Cq, where Cq is the PCR cycle at which significant 
fluorescence is measured from amplification of gene-specific probes). Data are mean +1 S.D. 
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Figure 16 shows that even when CaV channel mRNA expression is normalized using 
expression of a marker for cells that may also express CaV mRNA, these channels may still 








3.2.3 Expression of CaV channels in ovarian cancer cell lines 










3.2.3.2 CaL mRNA expression in ovarian cancer cell lines 
 
The efficiency of qPCR primers was first assessed. 10-fold dilutions of sample were made and 
qPCR performed. At 100% efficiency, each 10-fold increase in sample concentration should 
result in a decrease in Cq of 3.32 (log2(10)), although efficiency greater than 100% can occur 
Figure 16. RT-qPCR data from malignant ascites-derived cells. Log10 relative gene expression of CACNA1C and 
CACNA1D mRNA (calculated from the ratio of reference gene Cq and target gene Cq, where Cq is the PCR cycle 
at which significant fluorescence is measured from amplification of gene-specific probes). Data normalised to 
expression of ACTA2. 
Figure 17. RT-qPCR efficiency curves for CACNA1C, CACNA1D and the reference gene HPRT using the OVCAR-8 
OC cell line. Graphs show the Cq value (the PCR cycle at which significant fluorescence is measured from 
amplification of gene-specific probes) as a function of the starting amount cDNA (10-fold serial dilution). At 100% 
primer efficiency, the number of mRNA molecules doubles each cycle, meaning a 10-fold dilution should result 
in a slope of -3.32 (Log2(10)). Data represent mean Cq of triplicates +/- 1 S.D. 
 





































































if there is some inhibition of the polymerase enzyme by contaminants such as polysaccharides. 
or carry-over of reagents from the mRNA extraction phase (e.g. ethanol or phenol).   
Expression of mRNA coding for all 3 L-type α-subunit isotypes was also probed using qPCR 
in the OC cell lines (figure 18). While CACNA1S was not detected in any sample, SKOV-3 and 
OVCAR-3 cells expressed CACNA1C and CACNA1D, respectively. OVCAR-
8 equally expressed both CACNA1C and CACNA1D to an extent that is roughly 40% of that 
seen in either the SKOV-3 or the OVCAR-3. In addition, CaV1.2 and CaV1.3 proteins were both 















These data suggest that the CaV1.2 and CaV1.3 proteins are not expressed at the protein level 
in most serous ovarian tumours and are therefore unlikely to play any functional role at this 
stage of disease, although the 5% of patients who have overexpression in CACNA1C do have 
significantly lower survival than those without. It is important to note that as mentioned in the 
introduction, the CaV1.2 gene also contains a cryptic promoter coding for a transcription factor 
Figure 18. RT-qPCR data from ovarian cancer cell lines showing relative expression of CACNA1C and CACNA1D 
mRNA (calculated from the ratio of reference gene Cq and target gene Cq, where Cq is the PCR cycle at which 
significant fluorescence is measured from amplification of gene-specific probes) (n = 3 experiments). Data are 


























Figure 19. Expression of A) CaV1.2 and B) CaV1.3 in ovarian cancer cell lines using western blotting. 
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known as calcium channel associated transcriptional regulator (CCAT). However, expression 
of CCAT has been shown to be independent of the channel itself (Gomez-Ospina et al. 2013) 
and therefore any differences in patient survival are likely to be related to functions of the α-
subunit. 
One patient with mucinous ovarian carcinoma had higher expression of both CACNA1C and 
CACNA1D than any other sample that was likely not a result of any relative increase in the 
number of cancer cells or CAF. This correlated with the results from the IHC, in which the 
only sample with high staining for CaV1.3 was from a mucinous tumour. Mucinous tumours 
often display a glandular-type morphology which resembles that seen in colon cancer – which 
form tumours that are confirmed to express CaL (Fourbon et al. 2017). Contrary to data from 
the HPA, no serous tumours stained for CaV1.3. The reason for this is unknown, although this 
may be a result of difference in the antibody used. 
The results from the MAF derived cells suggest that L-type α-subunit mRNA expression 
profiles differ between patients with HGSOC, with CaV1.2 being the least variable. Whilst the 
expression of both CACNA1C and CACNA1D in the MAF derived cells could theoretically 
originate from fibroblasts or other cell types alone, the presence of CaL α-subunit mRNA and 
proteins in the cell lines lends support to the theory that these channels are expressed in ovarian 
cancer cells. 
Like the MAF derived primary cells, the ovarian cancer cell lines also displayed variability in 
the mRNA expression of the different CaL channels. This may reflect the origin of these cells, 
as the SKOV-3 and OVCAR-3 are derived from MAF of patients with serous adenocarcinoma 
(Mice, Fogh, and Orfeo 1977), (Hamilton et al. 1983). Although the origin of the OVCAR-8 is 
less clear, these cells do form ascites and large tumours with HGSOC histology in mice 
xenograft models (Mitra et al. 2015). 
In summary, it is likely that ovarian cancer cells begin expressing L-type CaV after they leave 
the primary tumour, when they become free floating ascites cells, possibly as a result of one of 
the many signalling mechanisms outlined in chapter 1. It is possible that the CaV1.3 is 
overexpressed more frequently in mucinous tumours than in serous, although further work is 
required to determine whether this is the case. 




4. Expression of CaV1.2 protein in malignant ascitic fluid derived cells 
4.1 Introduction 
 
Cancer cells in malignant ascitic fluid (MAF) are thought to be the main contributors to 
metastasis in ovarian cancer, to sites throughout the abdomen (Habyan et al. 2018). Free 
floating cells are already plastic enough to have been able to leave the primary tumour and may 
acquire further malignant capabilities as a result of the myriad of signalling molecules found 
in the ascitic fluid and detailed in the introduction. 
Cancer cells in malignant ascites are targetable in treatment regimens currently available to UK 
clinicians. There are several methods of intraperitoneal chemotherapy (IPC) which aim to 
target cancer cells in the abdomen, which include simple IPC, wherein a solution containing 
chemotherapeutics is delivered through a catheter during surgery or laparoscopic procedures. 
However, the most common method of IPC is hyperthermic intraperitoneal chemotherapy 
(HIPEC), which is usually performed after cytoreductive surgery (CRS) and involves infusion 
of a heated solution (40-48oC) containing chemotherapeutics such as cisplatin or carboplatin 
into the abdomen for around 90 minutes (NICE 2010). HIPEC has been evaluated most 
thoroughly in the treatment of peritoneal carcinomatosis of colorectal origin, although a case 
series of 96 patients with peritoneal metastasis and varying tumours of origin has shown 
significant improvement in quality of life compared to CRS alone (NICE 2010). Given the 
beneficial effects on recurrence-free and overall survival conferred by HIPEC (Van Driel et al. 
2018), it is important to quantify possible expression of targetable CaL in MAF derived cancer 
cells in the present work. 
Although in the previous chapter CACNA1D was the gene that displayed the highest mRNA in 
each of the MAF derived cells, this sample was from a mucinous ovarian cancer, a subtype that 
accounts for only 3% of the total ovarian cancer incidence. CaV1.2 (i.e. the CACNA1C gene 
product) was expressed more highly at the protein level in the cell lines and was chosen for 
further study in the present work, focussing on ovarian cancer MAF derived cells. In order to 
determine where CaV1.2 protein is detectable in MAF derived OC cells, flow cytometry was 
performed alongside an antibody against EpCAM - a widely used marker of cancer cells in OC 
(Akhter et al. 2018) (Q. Gao et al. 2019). The results of the flow cytometry are presented as 
dot plots – where for each cell measured, the intensity of fluorescence from the anti-EpCAM 
and anti-CaV1.2 antibodies are plotted on the X and Y axes, respectively.  
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To understand the possible function of CaV1.2 in cancer cells, it is important to determine its  
subcellular localisation. This was achieved by performing immunofluorescent staining for the 
protein alongside nuclear stains and a stain for EpCAM and then performing Pearson’s 
correlation analysis (as detailed in section 2.8). Determining the level of expression and 
localisation of CaV1.2 in these cells will be important to determine the potential role for this 
channel in ovarian cancer and may also help to determine whether the channel would be an 
effective therapeutic target. By staining for EpCAM (green in IF images from the present 
chapter), cell membranes of cancer cells can be visualised and the level of co-staining with 
CaV1.2 can be assessed. Possible nuclear staining of CaV1.2 can also be assessed through co-
staining with DAPI (blue in IF images form the present chapter).   
The most recent research in ovarian cancer has revealed a greater role for cancer associated 
fibroblasts (CAF) in OC progression, especially in MAF derived spheroid biology (Q. Gao et 
al. 2019), (Han et al. 2019). Therefore, it is important to determine the presence of these cells 
in samples derived from MAF. The type III intermediate filament vimentin is a widely used 
and reliable marker of fibroblasts (Nurmik et al. 2020). As such, immunostaining and 
subsequent morphological characterisation of vimentin positive cells was also performed on 
the same samples.  
The objectives of the current chapter are to a) determine whether CaV1.2 is expressed in ovarian 
MAF-derived cancer cells, b) determine in which cell membrane these channels are located 
and c) assess the prevalence of mesenchymal-type cells in ovarian MAF. 
 
4.2 Results 
4.2.1 CaV1.2 protein expression in malignant ascitic fluid derived cancer cells 
using flow cytometry 
 
The flow cytometry results in figure 20 suggest that the majority of MAF derived EpCAM+ 
serous ovarian cancer cells are also positive for CaV1.2. Samples 4, 13 and 15 all showed a 
strong positive correlation between these two markers. The only exception from this trend was 
observed in sample 12 (figure 20E), in which the majority of CaV1.2
+ cells were EpCAM-. 
However, this correlates with the results from the RT-qPCR experiment shown in figure 15, in 
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which this sample showed higher expression of ACTA2 than other samples and it was suggested 
that it contained a higher proportion of CAF and a lower number of cancer cells. 
Although the presence of cancer cells in sample 10 was confirmed with RT-qPCR using 
primers for EPCAM (figure 15), this sample had a low number of cells measured in the flow 
cytometry (figure 20F), which may be a result of this sample visibly consisting mainly of 
spheroids, which were filtered out prior to the experiment to prevent clogging of the flow 
cytometer. Figure 20A shows an example of cells from sample 10 after 24 hours in cell culture 
with visible aggregations of cells still visible. It is also possible that differences in the 
expression of cell adhesion molecules in the mucinous sample 10 prevented these cancer cell 
spheroids from adhering to the collagen-1 coated glass in the immunofluorescence experiment 
of the present chapter, which resulted in an enrichment of fibroblast-type cells observed in the 
vimentin staining (figure 27A). Some research groups have even used adherence to certain 
substrates as a method of separation of these two broad groups of ovarian ascites derived cells 




















4.2.2 CaV1.2 localisation in malignant ascitic fluid derived cancer cells using 
immunofluorescence 
 
To determine the subcellular localisation of CaV1.2 in MAF derived cells, immunofluorescent 
staining (EpCAM and CaV1.2) and subsequent Pearson’s correlation analysis was performed 
(three different regions of cells per image). 
The results from the Pearson’s correlation analysis of single cancer cells or cancer cell 
aggregates from the images in figures 21-25 all showed a positive correlation between staining 
for DAPI and staining for CaV1.2, with values ranging between r = 0.44 and r = 0.75.  When 
assessing r values, the commonly accepted thresholds for correlation are as follows: r<0.3 = 
none or very weak, 0.3<r<0.5 = weak, 0.5<r<0.7 = moderate, r>0.7 = strong. In the results 
presented in figure 26, 1/5 of the samples was calculated to have weak positive correlation 
(0.44), and 4/5 had a moderate positive correlation (0.5<r<0.7). 
DAPI is a fluorescent dye that exhibits a 20-fold increase in fluorescence intensity upon 
















Figure 20 A-E. Flow cytometry dot plots of intensity of CaV1.2 staining vs. EpCAM intensity in cells from malignant 
ascitic fluid. A – sample 4, B – sample 13, C – sample 15, D – sample 12, E – sample 10. F - % of CaV1.2- and CaV1.2+ 
cells in each sample. Horizontal line represents the mean percentage. Statistical significance was tested for using 




nuclei. This was also the case for the two samples stained with CaV1.2 and DAPI alone (figures 
24 and 25). The Coste’s P-value for all samples was 1, which signifies that none of the r values 
obtained from any of the 100 images with scrambled pixels had an r value that was higher than 
that obtained in the experimental image. Also, all of the samples analysed were relatively 
homogenous in their respective Pearson’s r values, with the ANOVA returning a p value of 
0.0796 based on the distribution of the F-statistic (figure 26). These analyses suggest that 
CaV1.2 displays significant nuclear colocalization in primary MAF derived ovarian cancer 
cells. 
It is possible that the staining for CaV1.2 seen in this experiment could be a result of ER 
retention of channels. However, the pattern of staining observed in no way mimics ER staining 
seen by other groups who performed specific ER staining on OC cells (Padmanabhan et al. 
2018). In the Padmanabhan paper, the staining with the ER label (α-calnexin) does not overlap 
that of the nucleus (DAPI).  
As mentioned in the introduction, CACNA1C also encodes the transcription factor CCAT 
which could theoretically show nuclear localisation upon use of a CaV1.2 primary antibody. 
However, this is not possible in this case as the antibody used in the present work was raised 
against aa 1507-1733 of the C-terminal tail and CCAT translation only begins at M2011 














Figure 21. IF staining of ascites derived cells (sample 4, 40X). A – Brightfield image and inset of EpCAM staining 
(shown in green), B – DAPI, C – CaV1.2, D – merge of C and D. Scale bar is 50 µm. E is the 2D channel intensity 

































Figure 22. IF staining of ascites derived cells (sample 11, 40X). A – Brightfield image and inset of EpCAM staining 
(shown in green), B – DAPI, C – CaV1.2, D – merge of C and D. Scale bar is 50 µm. E is the 2D channel intensity 







Figure 23. IF staining of ascites derived cells (sample 13, 40X). A – Brightfield image and inset of EpCAM staining 
(shown in green), B – DAPI, C – CaV1.2, D – merge of C and D. Scale bar is 50 µm. E is the 2D channel intensity 































Figure 24. IF staining of ascites derived cells (sample 5, 40X). A – Brightfield image, B – DAPI, C – CaV1.2, D – 
merge of C and D. Scale bar is 50 µm. E is the 2D channel intensity histograms from the associated Pearson’s 


































Figure 25. IF staining of ascites derived cells (sample 8, 40X). A – Brightfield image, B – DAPI, C – CaV1.2, D – 
merge of C and D. Scale bar is 50 µm. E is the 2D channel intensity histograms from the associated Pearson’s 

















4.2.3 Characterisation of cancer-associated fibroblast burden and morphology 
in malignant ascitic fluid derived cells 
 
In order to visualize morphology of mesenchymal-type cells from MAF, immunofluorescent 
staining for vimentin was performed. 
Staining for vimentin revealed that several of the samples had a high number of mesenchymal-
type cells, likely CAF (figure 27). Data from sample 11 (figure 27B) showed a polyploid giant 
cell (PGC), which was 0.1 mm in length and contained five nuclei. The data from sample 13 
(figure 27D) reveal that cancer cells (large circular nuclei with prominent nucleoli) are negative 
for vimentin. This image also confirms previous observations that suggest ovarian spheroids 
are formed of a central core of CAF, which stain for vimentin and are shown in figure 27D 
(white arrows) migrating away from the cancer cells (Q. Gao et al. 2019). These cells are vital 
for spheroid formation and also increase the ability of spheroids to adhere to and clear the 





Figure 26. Pearson’s r values from different MAF derived OC cells, representing colocalization between the 
nucleus (DAPI) and CaV1.2 (Alexa Fluor 647). Data are mean +1 SD. As data are from >3 independent samples, 
statistical significance was analysed using a one-way ANOVA. 




































Figure 27. IF staining of vimentin (Alex Fluor 647, red) and nuclei (DAPI, blue) in ovarian ascites derived cells 
from sample A – 10, B and C – 11 and D – 13. White arrows indicate cells which are likely CAF, migrating away 






































































Voltage-gated ion channels were once thought to be predominantly expressed at the plasma 







Figure 28. No primary antibody negative controls for non-specific staining of Alexa Fluor 488 (column 1) and 
Alexa Fluor 647 (column 2) secondary antibody in A – sample 4, B – sample 5, C – sample 8, D – sample 9, E – 
sample 10, F – sample 11, G – sample 13. 
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revealed using fluorescence-activated cell sorting (FACS) on permeabilized and non-
permeabilized HTC116 cells that 70% of cells display intracellular CaV1.3 localisation and this 
cytoplasmic and nuclear localisation was confirmed with confocal microscopy (Fourbon et al. 
2017). The voltage gated potassium channel KV1.3 is also nuclear expressed in the MCF7 
(breast), A549 (lung) and SNU-484 (gastric) cancer cell lines and is a functional nuclear 
channel in the A549 (Jang et al. 2015). In addition to the cytoplasm, Ca2+ is also found in the 
nucleoplasm at the same concentration (100 nM) and in the ER and perinuclear space at 100-
300 µM (Matzke, Weiger, and Matzke 2010). Common Ca2+ channels found at the inner 
nuclear membrane include the ryanodine receptor (RyR), while the outer nuclear membrane 
contains both RyRs and IP3Rs (Matzke, Weiger, and Matzke 2010). Nucleoplasmic Ca
2+ is 
thought to facilitate complex programs of gene transcription and cell cycle regulation. Whilst 
literature on nuclear expression of voltage-gated ion channels is sparse, it could theoretically 
be a novel mechanism by which certain cancer cells enact changes in gene expression. 
Some of the results from the IF staining for EpCAM in the present work had a high amount of 
background staining. This could be a result of binding of primary antibodies to extracellular 
EpCAM released via exosomes, via the process that was detailed in the introduction. It is 
known that extracellular vesicles from OC cells express a variety of different integrins, which 
allow them to adhere to the ECM in different anatomical locations preferentially (Kosaka et al. 
2019). Although the cells were washed, it is possible that some EpCAM-containing vesicles 
adhered via their integrin proteins to the collagen-1 coating, remained after fixation and were 
responsible for the background staining in these images.  
The discovery of the PGC was unexpected, although polyploid giant cancer cells (PGCC) are 
a feature of serous ovarian tumours, where their incidence is positively associated with tumour 
grade (L. Zhang et al. 2014). PGCC are also seen in murine tumours produced via xenograft of 
the human ovarian ascites-derived OVCAR-3 cell line (Hamilton et al. 1983). Other studies 
using the HEY ovarian cancer cell line have shown HEY PGCC to express significantly more 
vimentin than control cells both in vitro and in vivo using biopsies of tumours from xenograft 
mice. Tumours derived from ovarian cancer PGCC also display higher levels of stem cell 
markers including CD44 and CD133 are associated with higher tumorigenicity (S. Zhang et al. 
2014). 
The ascites derived cancer cells observed in figures 20-24 are all rounded with no obvious 
projections, in contrast with the vimentin+ cells present in figure 26. Maintenance of a rounded 
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cell membrane has been shown in other studies that have characterised the migration of primary 
ovarian cancer cells as amoeboid (Kapoor et al. 2018). As mentioned in the introduction, many 
primary ovarian cancer cells are thought to maintain an epithelial phenotype and MAF derived 
OC cells are heterogenous in their expression of E-cadherin (Habyan et al. 2018) . This is in 
contrast with many of the ovarian cancer cell lines (including some used in the present work), 
which display a mesenchymal phenotype and migration. While their role in division of cancer 
cells is unknown, CaV are known to function in division of neuroendocrine cells, where 
channels are present at the midbody during cytokinesis (Loechner et al. 2009). 
5. The effect of pharmacological inhibition of L-type CaV on malignant characteristics of 
ovarian cancer cells 
5.1 Introduction 
 
There are a number of possible ways that OC cells can utilise motility to facilitate tissue 
invasion. 80% of all women with serous ovarian cancer have omental metastases (Nieman et 
al. 2011) and in order to colonise the omentum, cells and spheroids that are free floating in the 
malignant ascitic fluid (MAF) or peritoneal fluid must adhere to the surface of the outer 
omental layer, which is composed of a monolayer of mesothelial cells expressing fibronectin 
(Kenny et al. 2014). For this reason, it is important to understand how OC cells move on 
fibronectin and in the context of the present work, whether this process is dependent upon CaL. 
This process can be approximated using wound-healing assays with ovarian cancer cell lines. 
Substrate stiffness is a key indicator of migratory capacity in cells, and is described by Young’s 
modulus, which is the ratio of the stress (pressure per cross-sectional area) divided by the strain 
(the ratio of the length of the deformed material to its original length). Fibronectin on glass has 
a high stiffness, with a Young’s modulus of 70 GPa, a value likely to be higher than the human 
peritoneum (as yet unmeasured) (McKenzie et al. 2018), but one that does promote a migratory 
phenotype in ovarian cancer cells (McKenzie et al. 2018). 
After initial deposition onto the mesothelial layer and mesothelial clearance have occurred, 
ovarian cancer cells can invade into the underlying omental basement membrane (known 
clinically as ‘omental caking’), which is composed of collagen I, collagen IV, laminin and 
fibronectin (Witz et al. 2001). To probe the possible contribution of CaL to the initial stage of 
cancer cell interaction with the omentum, OC cell lines grown +/- fibronectin were subject to 
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co-immunoprecipitation for CaV1.2 and blotted for α5 integrin – the main cell adhesion 
molecule known to facilitate interaction with fibronectin in OC (Q. Gao et al. 2019). Studies 
using HEK cells have shown that CaV1.2 is able to spatially associate with α5 integrin upon 
ligation of the latter to fibronectin, in a process that enhances the current amplitude through 
CaV1.2 (Chao et al. 2011). The later stage of omental caking involving progressive invasion 
into the omentum was also modelled with a 3D invasion assay using basement membrane 
extract. 
As mentioned in the introduction, CaL are sensitive to DHP antagonism. In the literature, these 
channels are also frequently associated with migration and invasion and it is 
possible that they play a similar role in ovarian cancer cells. To determine if this is the case in 
the present work, the 2D migration and 3D invasion assays were performed with ovarian cancer 
cell lines and MAF derived cells treated with nifedipine – a tocolytic (medication used to 
supress premature labour) with an oral LD50 of around 500 mg/kg in mice (Czarnecka and 
Kubik-bogucka 1993). The concentrations of nifedipine used were 3µM and 10 µM, which are 
in the same range as other studies using nifedipine to assess the potential role of CaV in cell 
migration (Guo et al. 2018), and means the lowest concentration was around eight times higher 
than the peak plasma concentration of around 367 nM (Papatsonis et al. 2007) achieved after 
60 mg nifedipine in tablet form. In order to control for possible effects on cell viability, these 
were performed alongside cell viability, as well as apoptosis/necrosis assays, which use flow 
cytometry on cell stained with propidium iodide (a membrane-impermeable fluorescent DNA 
dye) to measure necrosis, and fluorophore-labelled annexin V (a protein with high affinity for 
phosphatidylserine residues) to measure apoptosis. Fluorescence intensity is then plotted for 
each dye on each axis. The effect of CaL antagonism on spheroid formation in OC cell lines 
was also assessed. These experiments were also performed alongside luminescence-based 
spheroid viability assays. 
5.2 Results 
5.2.1 The effect of CaL inhibition on viability, necrosis, and apoptosis in OC cell 
lines 
 
To determine if DHP treatment induces apoptosis or necrosis in OC cells, cell lines were treated 
with nifedipine and apoptosis and necrosis measured with an annexin V apoptosis assay. The 
results for the apoptosis/necrosis assay showed no significant effect of treatment upon the 
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OVCAR-8 cells (figure 29), although apoptosis was induced in SKOV-3 by 3 and 10 µM 
nifedipine (figures 30C and 30D, respectively). SKOV-3 were extremely sensitive to the 
concentration of nifedipine, with a 7 micromolar increase in nifedipine concentration resulting 
in a 4-fold increase in the number of apoptotic cells (figure 31) as assessed via multiple t-tests 
(Siegel 1990). The results from the viability assay at figure 32 showed no significant effect of 
nifedipine on either ovarian cancer cell line used.  Given the apoptotic effect of nifedipine on 
SKOV-3 cells, it was decided to continue the migration and invasion experiments on the 
OVCAR-8, which did not show significant necrosis or apoptosis upon treatment. 
  
Figure 29. Flow cytometric measurement of necrosis (PI – propidium iodide) and apoptosis (Annexin) in OVCAR-
8 cells treated for 24 hours with A) vehicle control (1% EtOH), B) 3 µM nifedipine and C) 10 µM nifedipine. Dot 
plots represent intensity of staining for individual cells in each treatment condition. Tables below show 
proportion of total cells in each quadrant. 
 
Figure 30. Flow cytometric measurement of necrosis (PI – propidium iodide) and apoptosis (Annexin) in SKOV-3 
cells treated for 24 hours with A) vehicle control (1% EtOH), B) 3 µM nifedipine and C) 10 µM nifedipine. Dot 
plots represent intensity of staining for individual cells in each treatment condition. Tables below show 




















































5.2.2 The effect of CaL inhibition on 2D migration of OVCAR-8 cells 
 
Next, the effect of L-type inhibition with felodipine (a second generation DHP used as a 
substitute for nifedipine when the latter was unavailable) on rate of OVCAR-8 wound closure 
on fibronectin was assessed using the wound healing assay as described in section 2.3.1. Figure 
33 shows the amount of wound healing at 0, 6, 12 and 18 hours after the initial scratch at 
different concentrations of the felodipine. The results show a significant decrease in percentage 
wound closure at 12 and 18 hours in the presence of both 3 and 10 µM felodipine. 
Figure 32. Viability of OVCAR-8 and SKOV-3 cell monolayers measured using resazurin, after 24-hour treatment 
with indicated concentration of the CaL antagonist nifedipine. n = 3 experiments. Data represent mean +/- 1 S.D. 
 
Figure 31. Analysis of the percentage apoptotic ovarian cancer cells in the presence of nifedipine. Data represent 
mean +/- 1 S.D. Statistical significance was analysed using multiple t-tests. **** = p < 0.0001. Multiple t-tests 



























This is especially noticeable at 18 hours, where wound healing was almost completed in the 
control cells, whereas in the cells treated with 10 µM felodipine showed only a minimal 



















































Figure 33. A) Percentage wound closure over time in the presence of the CaL antagonist felodipine using 
the OVCAR-8 OC cell line. Statistical significance was measured using a repeated measures ANOVA, which 
is used to compared group means where the participants are the same in each group (in this case, assessed 





5.2.3 The effect of CaL inhibition on 3D invasion of OVCAR-8 cells and 
malignant ascitic fluid derived cells  
5.2.3.1 Invasion of OVCAR-8 cells into basement membrane extract 
 
To determine if dihydropyridine treatment had any effect on the ability of OC cell lines and 
MAF derived cells to invade into basement membrane extract, transwell invasion assays were 
performed in the presence of the dihydropyridine nifedipine. If CaL inhibition does inhibit 
invasion, it would be expected that a decrease in the number of invasive cells would be 
observed compared to control condition in the transwell assays. The results from the invasion 
assays using the OVCAR-8 cells at figures 34 show no significant decrease in invasive capacity 







5.2.3.2 Invasion of malignant ascitic fluid derived cells into basement membrane extract  
A significant decrease in invasion was observed in only one sample from the MAF derived 
cells (sample 13, figure 35). Sample 10 was tested alone and CaL inhibition also showed no 







Figure 34. The effect of nifedipine on invasion of OVCAR-8 OC cells into basement membrane extract after 24 
hours. n = 3 experiments. Image on the right is an example of the transwell after the experiment, for qualitative 
comparison with other samples in this chapter (taken at 20X magnification) Data are mean +/- 1 S.D.  
 
 
Figure 35. The effect of 10 µM nifedipine on invasion of MAF derived cells into basement membrane extract 
after 24 hours. Image on the right is an example of the transwell after the experiment, for qualitative comparison 
with other samples in this chapter (taken at 20X magnification Data are mean +/- 1 S.D. As data were normally 


























































5.2.4 The effect of CaL inhibition on ovarian cancer cell line spheroid formation 
and viability 
 
In order to determine if OC cell line spheroids displayed different functions for CaL channels, 
spheroid viability assays were performed using spheroids generated from OC cell lines 
OVCAR-8 spheroids showed generally higher disaggregation after 24 hours when plated on 
fibronectin than when plated on tissue culture plastic alone. Treatment of nascent OVCAR-8 
and SKOV-3 spheroids with either 3 or 10 µM nifedipine had no effect on the ability to form 
spheroids after 24 hours. The results from the spheroid viability assay (figure 37) also show no 
significant decrease in viability in either the OVCAR-8 or SKOV-3 OC cells.  
   
Figure 36. The effect of 10 µM nifedipine on invasion of MAF derived cells (sample 10) into basement membrane 
extract after 24 hours. Image on the right is an example of the transwell after the experiment, for qualitative 















































Figure 37. Viability of OVCAR-8 and SKOV-3 cell spheroids measured using a resazurin assay after 24-hour 
treatment with indicated concentration of nifedipine. Data are mean +/- 1 S.D. As data were normally distributed 





5.2.5 Association of CaV1.2 with integrin α5 
 
To probe whether CaL are involved in the molecular pathway by which OC cells adhere to 
fibronectin expressed by mesothelial cells of the human omentum, OC cell lines grown on 
fibronectin were subject to co-immunoprecipitation of CaV1.2 followed by western blotting for 
integrin α5. The results from the immunoprecipitation experiment did not show any association 
between CaV1.2 and integrin α5, although integrin α5 was confirmed to be present in the OC 
cell line monolayer (figure 38A). Although it was clear that no bands for α5 integrin were 
present, the IP lanes did contain a number of non-specific bands (red arrow), which were also 
present in the negative control lanes (figure 38, neat beads + lysate). This was a result of non-
specific binding of proteins to the Dynabeads, and a similar pattern of bands have been 
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Figure 38. Measurement of association of CaV1.2 with integrin α5 in OC cell lines using western blotting. A) 
lanes 1-4: positive control for α5 integrin expression, lanes 5-8: experimental IP condition. B) lanes 1-4: 
negative control for α5 integrin IP, lanes 5-8: experimental IP condition. Non- specific bands caused by non-






Whilst nifedipine is an inhibitor of both CaL and p-glycoprotein (Pgp) (Viale et al. 2011) other 
studies have shown that both SKOV-3 (Biol et al. 1991), (Y. Gao et al. 2014) and OVCAR-8 
(Y. Gao et al. 2014) cells express a negligible amount of Pgp protein, meaning that the 
nifedipine-induced apoptosis observed in the SKOV-3 in the present work was not a result of 
Pgp inhibition. In support of this is the observation that nifedipine also induces concentration-
dependent apoptosis in the A2780 OC cell line (Chovancova et al. 2020). This means that the 
apoptosis observed in SKOV-3 in this chapter and shown in figure 31 is likely a result of 
nifedipine-mediated inhibition of CaL. 
Drug-resistant OC cell lines such as SKOV-3TR and OVCAR-8TR do express Pgp protein (Y. 
Gao et al. 2014). The ABCB1 gene that codes for Pgp displays low expression in normal 
OVCAR-8 cells. However, in the OVCAR-8-derived multiple drug resistant cell line 
NCI/ADR-RES, expression of this gene is increased 122-fold (Vert et al. 2018). Whilst other 
studies have shown almost identical levels of apoptosis in SKOV-3 cells when treated with 
similar concentrations of the specific Pgp antagonist valspodar alongside cisplatin, Pgp 
antagonism alone did not result in any significant increase in apoptosis, with 90% of cell 
unchanged (Zalewski et al. 2019).   
Nifedipine also has some affinity for CaT channels (Shcheglovitov et al. 2005). While there is 
no indication of the effect of CaT inhibition on apoptosis in SKOV-3 in the literature, studies 
have shown 10 µM mibefradil to have no effect on cell growth of SKOV-3 over 24 hours 
(Dziegielewska et al. 2016). 
The results from the OVCAR-8 migration assays suggest that there are significant differences 
in the mechanisms of 2D migration and 3D invasion in OC cells, with CaL inhibition affecting 
motility only in the former scenario. In addition to changes determined by substrate stiffness, 
variation in the pathways of migration may result from differential ligand engagement between 
the 2D fibronectin and 3D basement membrane extract (BME) model. As well as containing a 
low amount of fibronectin, the BME used in these experiments contains other common ECM 
proteins including laminin, collagen IV, entactin and heparin sulphate proteoglycans (Gibco 
2019). Other studies have shown that differential binding of ECM components to cell surface 
molecules can lead to upregulation of specific motility genes, as well as trafficking of protein 
cargo to the plasma membrane (Ulrich, Pardo, and Kumar 2009). Invasion is thought to rely 
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less heavily on release of proteolytic enzymes and more on increased deformability of the cells 
themselves (Wolf et al. 2002). 
As mentioned in the introduction, substrates with differing Young’s moduli can lead to vastly 
different phenotypes in cancer cells, with softer substrate favouring amoeboid-type migration. 
According to this theory, cancer cells migrating in the 2D model of fibronectin used in the 
present work would favour mesenchymal-type migration and those migrating through the BME 
would favour amoeboid-type.  
It is therefore likely that in the present work, nifedipine induced apoptosis in SKOV-3 cells as 
a result of CaL inhibition. It may be that the function of CaL differs entirely between SKOV-3 
and OVCAR-8 cells, being important for proliferation/viability in the former and 2D 
mesenchymal migration in the latter. CaL inhibition prevented migration only in a 2D, high 
substrate stiffness model.  




Whilst not traditionally excitable cells, it is clear that cells from different cancer may express 
functional voltage gated channels that are measurable via electrophysiology (Abel et al. 1995), 
(Toselli et al. 1991). However, there have been few studies that have measured Ca2+ currents 
in OC cells, although one recent study using OC cell lines has shown evidence of a strong non-
inactivating inward current, which becomes active at ~-30 mV and is strongly inhibited by the 
DHP manidipine (Lee et al. 2020). 
In the present work, the results from chapters 4-6 confirmed that CaV1.2 was expressed in OC 
cells from MAF as well as OC cell lines and also that antagonism with nifedipine leads to 
differential effects on apoptosis and migration depending on the experimental model and cell 
line. It is also important however, to determine whether CaL in OC cells are functional and 
allow influx of Ca2+ upon depolarisation. In order to test this, electrophysiological experiments 
were performed on MAF derived cells and OC cell lines using the patch clamp technique. To 
provide further evidence for the presence of functional CaL in OC cells, cytosolic Ca
2+ fluxes 
were also measured via fluorescence spectroscopy using the Ca2+-sensitive dye Fluo4-AM in 
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cells treated with the CaV agonist Bay K8644, which is a DHP-type drug that causes opening 
of CaV and results in current flow across the cell membrane through CaV channels. 
In order to assess whether the electrophysiological setup was optimal for measurement of CaV 
current, the first patch clamp experiments were performed using SH-SY5Y glioblastoma cells. 
The presence of inward CaL current in these cells has been known for many years and these 
cells work as a positive control (Toselli et al. 1991). Once the presence of functional CaL was 
demonstrated in the SH-SY5Y, these cells were then also used a positive control for CaL-
mediated Ca2+ influx in the experiment to measure cytosolic Ca2+ in OC cells. 
The objectives of the current chapter are to determine whether OC cell lines and cells from 
MAF express functional CaL. 
 
6.2 Results 
6.2.1 Electrophysiological measurement of Ca2+ current in SH-SY5Y 
glioblastoma cells 
 
SH-SY5Y glioblastoma cells were used a positive control for CaV channel current and tested 
using patch clamp electrophysiology. Inward Ca2+ current through CaV and carried by Ba
2+ was 
observed in the positive control (SH-SY5Y – figure 39). Both the threshold potential of -30 
mV (figure 39A) and the duration of the current decay (figure 39B) signify that this was an L-
type voltage gated Ca2+ current. However, the voltage at peak current (-20 mV) was 
hyperpolarised compared to values seen elsewhere (Toselli et al. 1991). This likely occurred 
as a result of a series resistance error caused by improper gigaseal formation, which lead to 
inadequate holding of cell potential, triggering action potential firing (Sakmann and Neher 
1995). The gigaseal is the extremely tight physical connection in which the cell membrane 
seals around the edge of the glass micropipette tip, forming a high-resistance connection 
between the micropipette and the inside of the cell. When the gigaseal is not properly formed, 
the membrane potential may rise due to movement of positive ions into the cell through the 
gap between the micropipette and the cell membrane. This means the actual membrane voltage 
does not perfectly match the command voltage set by the investigator and can cause action 




Figure 39. Patch-clamp electrophysiological positive control for inward L-type voltage-gated Ca2+ channel 
activation using SH-SY5Y glioblastoma cells grown in DMEM-F12 + 10% FBS and plated on poly-D-lysine 
overnight. A) Current-voltage plot, B) raw trace of current (Im_primary) and C) applied voltage (Vm_sec) vs. time 





























6.2.2 Electrophysiological measurement of Ca2+ current in ovarian cancer cell 
lines 
 
Figures 40-42 show the data from the whole cell patch clamp experiments, with membrane 
current as a function of voltage, with recordings taken after holding the cell for 200 ms at the 
specified voltage. CaL currents were not observed in any of the OC cell lines tested (figure 40). 
As reported previously and is consistent with cancer cells in general (M. Yang and Brackenbury 
2013), both SKOV-3 and OVCAR-8 had a relatively depolarised VM, between -20 and -10 mV 
(shown on the graphs at the point where the curve crosses the x-axis). For both cell lines, 
experiments were performed on either poly-D-lysine or fibronectin and the results were the 
same. TRP current was not observed in any of the SKOV-3 cells probed (n = 10) but was 
observed in an OVCAR-8 cell (figure 40C). Given the conditions of the solutions used and the 
steep positive slope of the IV plot at negative voltages, this was likely carried by the Ca2+-
























































6.2.3 Electrophysiological measurement of Ca2+ current in primary ovarian 
cancer cells 
 
Current-voltage traces from individual MAF derived OM10 cells showed similar VM potential 
to the SKOV-3 and OVCAR-8 cells, between -20 and -10 mV (figure 41A). One OM10 single 
cell displayed a current resembling those carried by TRPV5 and TRPV6 (figure 41B) and also 
seen in the OVCAR-8. One OM10 single cell also displayed an inward voltage gated current, 
likely to be carried by CaL (figure 41C). This cell also displayed a continuing net outward 
current upon depolarisations around +50 and +60 mV. As mentioned in the introduction, using 
Ba2+ as a replacement for Ca2+ results in delayed inactivation kinetics, as a result of poor 
affinity for intracellular Ca2+-binding proteins such as calmodulin and is likely responsible for 
the delayed inactivation seen in this cell.   



































Figure 40. Current-voltage plots derived from patch-clamp electrophysiological recording of SKOV-3 and OVCAR-
8 cells grown in RPMI + 10% FBS and plated on poly-D-lysine overnight. Cells were held at -80 mV before the 
protocol of 10 mV increments between -60 and +60 mV was begun. Data suggest no voltage-gated current in 


























6.2.4 Electrophysiological measurement of Ca2+ current in primary ovarian 
cancer spheroids 
 
Patch clamp experiments were attempted on MAF derived spheroids. TRP currents were 
recorded in three spheroids from OM10 (figure 42). OM10 spheroids were taken from different 
aliquots of the sample and were measured in separate experiments. No cells from the MAF 
derived OM16 showed evidence of any appreciable Ca2+ current in these experiments (figure 
42). 








































Figure 41. Current-voltage plots derived from patch-clamp electrophysiological recording of OM10 single cells 
grown in 1:1 medium 199/medium 105 + 20% FBS and plated on collagen-1 overnight. Cells were held at -80 mV 
before the protocol of 10 mV increments between -60 and +60 mV was begun. Data suggest no voltage-gated 
current in cells 1 and 2, but a possible TRP-mediated current in cell 3 and a high probability of a CaL-mediated 







Electrophysiological measurements in the same conditions were also attempted using spheroids 
created from OVCAR-8 cells, although a patch clamp could not be achieved, as generally the 
















6.2.5  Fluorescent measurement of cytosolic Ca2+ flux from cell monolayers 
using Fluo4 
 
In order to confirm the validity of the electrophysiology results, CaL-dependent Ca
2+ influx into 
SH-SY5Y glioblastoma cells (positive control), OVCAR-8 and SKOV-3 cells was measured 
fluorometrically using the Ca2+ sensitive dye Fluo4-AM in the presence of the CaL agonist Bay 
K8644 (figure 43). 



































































Figure 42. Current-voltage plots derived from patch-clamp electrophysiological recording of OM10 spheroids 
grown in 1:1 medium 199/medium 105 + 20% FBS and plated on collagen-1 overnight. Cells were held at -80 mV 
before the protocol of 10 mV increments between -60 and +60 mV was begun. Spheroid 1 showed no 
appreciable voltage-gated current, spheroid 2 and 3 showed a possible TRP-mediated current and three cells 




Consistent with the results from the electrophysiology and other studies that have measured 
Ca2+ influx with Fluo4 in this cell line (Domracheva et al. 2020), a dose-dependent increase in 
intracellular Ca2+ was observed in the SH-SY5Y glioblastoma positive control cells upon 
treatment with the CaV agonist Bay K8644 (figure 43A). However, a significant decrease in the 
fluorescence signal was observed in the OVCAR-8 cells in the same conditions (figure 43B), 
and non-significant decrease was observed in the SKOV-3 (figure 43C), although the 
individual readings for the cell lines were more variable than for the positive control and the 
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No CaL current was detected in the OC cell lines in the present chapter. However, CaL channels 
were detected at the SKOV-3 and OVCAR-8 cell membrane via western blotting in chapter 4 
and collective OVCAR-8 migration was shown to be sensitive to DHP in chapter 5. A possible 
reason for the absence of measured flux in the present chapter is because CaL channels facilitate 
Figure 44. Representative current-voltage traces for different TRP channels as published by the International 
Union of Pharmacology (IUPHAR) - a) TRPC1 + TRPC5 heteromer, b) TRPM5 and c) TRPV5/TRPV6.  
 
Figure 43. Measurement of Bay K8644-stimulated Ca2+ influx into cancer cells using Fluo4-AM. A) SH-SY5Y cells 
B) OVCAR-8 cells and C) SKOV-3 cells were grown for 24 hours, before incubation in 4.5 µM Fluo4-AM and 
subsequent treatment with the indicated concentrations of the CaV agonist Bay K8644. Statistical significance 
was analysed using a two-way repeated measures ANOVA. **** is p<0.0001, *** is p = 0.0001 to 0.001, ** is p 
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migration via Ca2+ ‘sparklets’ – which are tiny local increases in Ca2+ influx involved in sensing 
the external environment and maintaining the front-rear axis of the cell during migration (Man 
et al. 2016). Ca2+ sparklets can be facilitated by the activation of single CaV channels (Santana 
and Navedo 2009) meaning they are too small in magnitude to be measured via 
electrophysiology, as the current through a single CaV channel is ~0.5 pA (Santana and Navedo 
2009). These sparklets have been shown in other studies modelling migration of mesenchymal 
MDA-MB-231 breast cancer cells and have a low frequency of activation (0.442 mHz per 100 
µm2 cell area) (Man et al. 2016), which would also decrease the probability of measuring their 
activation with plate-based fluorescence assays.  
The observation that functional TRP channels exist in the OVCAR-8 was unexpected, although 
it is consistent with data from other cancers that study the role of these channels in migration 
(Canales et al. 2019). During cell migration, different TRP channels may be engaged in 
processes including regulation of actin dynamics at the leading edge, focal adhesion formation 
and mechanotransduction that are read as cues in response to the composition of the 
extracellular environment and which affect the direction of migration (Canales et al. 2019). In 
most cancers including breast (Meng et al. 2013), pancreatic ductal adenocarcinoma 
(Rybarczyk et al. 2017) and nasopharyngeal (J. P. Chen et al. 2015), it is TRPM7 that has been 
identified as the main contributor to migration, although current carried by this channel was 
not detected in the present work. 
Spheroids from ovarian cancer are known to have a heterogenous cellular composition, with a 
central core of CAF and cancer cells, surrounded by a peripheral shell of cancer cells 
punctuated with leucocytes including macrophages, which are also thought to drive ovarian 
spheroid formation (Yin et al. 2016). The evidence from OM10 (figure 42), suggests that 
several types of functional TRP channels expressed by either cancer cells or leucocytes are 
found at the periphery of ovarian spheroids and may facilitate signalling pathways that could 
ultimately affect disease progression or maintenance in patients. For example, downstream 
effects associated with activation of TRPC5 in macrophages includes polarization to an M1 






7 General Discussion and Conclusion 
 
7.1 General discussion 
 
7.1.1 CaL are expressed in malignant ascitic fluid derived cells but not tumours 
 
The results of the expression data in chapter 3 suggest that CaV1.2 (CACNA1C) and CaV1.3 
(CACNA1D) are the CaL subtypes that are expressed as protein in OC, showing mRNA and 
protein expression in OC cell lines and mRNA expression in MAF derived cells. The data from 
the qPCR and IHC experiments suggest that these CaL are not frequently expressed in HGSOC 
tumours. 
There are discrepancies between the results obtained in the present work for the staining of 
HGSOC tumours for CaV1.3 (all negative) and results seen in the Human Protein Atlas 
(HGSOC tumours mostly positive). It is possible that the widespread staining for CaV1.3 seen 
in the HPA may be a result of cross-reactivity of antibodies with the C-terminal tail of CaV1.3 
which as detailed in the introduction, can show cross reactivity with a transcription factor, 
which is expressed from the 3’ end of the CACNA1C gene and contains the same sequence of 
proteins as the C-terminal end of the channel (Lu et al. 2015). 
The present work showed no difference in the relative expression of CaV1.2 mRNA between 
stage 3 tumours and MAF derived cells but a large increase in the expression of the protein in 
MAF derived cells, suggesting that the latter is a result of release of translational repression or 
decreased protein degradation. Data in this work suggest a loss of adherence to the primary 
tumour is required for CaV1.2 expression and in cells derived from MAF, both single cancer 
cells and those found as spheroids displayed this protein. Significant upregulation of CaV1.2 
and CaV1.3 mRNA in MAF derived cells and CaV1.3 protein in tumours has also been shown 
to be a feature of mucinous OC in the present work. 
7.1.2 CaL are commonly nuclear expressed in malignant ascitic fluid derived ovarian 
cancer cells 
 
Data from the IF experiment (chapter 4) showed clearly that CaV1.2 was localised to either the 
inner or outer nuclear membrane in MAF derived primary OC cells and spheroids. Further 
work is required to determine whether these channels are functional - although if so, there are 
a number of ways in which they could promote malignancy. Nuclear Ca2+ is regulated 
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independently of cytosolic Ca2+ in other cancer cells (Badminton, Campbell, and Rembold 
1996) and studies over the last decade have shown nuclear Ca2+ signals to be important in cell 
cycle control in cancer (Parkash and Asotra 2010). Experiments involving buffering of nuclear 
Ca2+ in HepG2 cells via exogenous expression of parvalbumin have demonstrated significantly 
decreased tumour burden upon subcutaneous injection into mice, which resulted from 
decreased cell proliferation (Pusl et al. 2002). Increases in nuclear Ca2+ are required for the 
functioning of Ca2+-responsive transcriptional regulators such as downstream regulatory 
element antagonist modulator (DREAM) and transcription factors such as cyclic AMP 
response element-binding protein (CREB) – both of which are involved in cell cycle control 
(Bootman et al. 2009). 
Consistent with other studies, the MAF derived CaV1.2-expressing cancer cells in the present 
work retained an epithelial phenotype (Latifi et al. 2012), being EpCAM+ and vimentin-. The 
majority of CaV1.2 being localised to the nuclear membranes does however mean that channels 
in MAF derived cancer cells are amenable to targeting only by lipophilic DHP. However, DHP 
antagonism (chapter 5) did inhibit migration in a 2D model using a mesenchymally migrating 
OC cell line (OVCAR-8), whilst having no effect on invasion in either the cell lines or MAF 
derived cells. 
Studies over the last decade have revealed two stages of OC progression in which cancer cells 
display a mesenchymal phenotype – during the migration of STIC cells from the fallopian tube 
to the ovary and the invasion of the mesothelial lining (Loret et al. 2019). EMT involves 
downregulation of proteins expressed in normal epithelia including E-cadherin, occludins, 
claudins, EpCAM and certain cytokeratins important for formation of desmosomes. From these 
results it seems that CaL may play differing roles in HGSOC cells with an epithelial phenotype 
and HGSOC cells with a mesenchymal phenotype. The scheme of CaV1.2 expression during 
OC progression is as follows: 1) STIC cells within the fallopian tube first undergo EMT and 
migrate to the ovary. 2) Once at the ovary (or other anatomical location of primary tumour), 
STIC cells undergo mesenchymal to epithelial transition (MET), forming the primary tumour 
and at this stage, cells are negative for CaV1.2. 3) Then, after having broken away off from the 
primary tumour, cells and spheroids floating in the ascitic fluid begin expressing CaV1.2 at the 
nuclear membrane. 4) Later, it is likely that some of these cells under the influence of TGF-
beta signalling and shear stress from the ascitic fluid undergo EMT and are able to adhere to 
the fibronectin of the mesothelial monolayer via α5β1 integrin (Q. Gao et al. 2019). It is possible 
that these cells then utilize CaV1.2/CaV1.3 to migrate in 2D on the fibronectin layer before 
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finding optimal sites for metastatic tumour growth, at which point the cells undergo 
mesenchymal-to-epithelial transition (MET). 
In addition to mesenchymal migration of OC cells, there is a growing consensus that CAF play 
a major role in metastasis of this disease and these cells rearrange ECM at the metastatic site 
to create an environment more conducive to tumour formation (Nurmik et al. 2020). Although 
literature on the migration of CAF is sparse, it is likely that they utilize the same migratory 
machinery as other mesenchymally-migrating cells and will also be sensitive to CaL 
antagonism. Data from chapter 4 of the present research appears to confirm recent observations 
that OC spheroids are formed of a shell of cancer cells surrounding a core of one or more CAF 
– which are themselves critical facilitators of spheroid formation (Q. Gao et al. 2019). 
7.1.3 Ovarian cancer cell lines display differing responses to CaV antagonism 
 
Whilst the two OC cell lines used in the present work displayed a similar level of expression 
of plasma membrane CaL, they exhibited different responses to DHP treatment. OC cells 
display a large phenotypic diversity, and recent research is placing an greater emphasis on 
identifying these cell types and understanding their role in the disease (Strauss et al. 2011) and 
it is not surprising that cells may exhibit differing programs of migration and apoptosis. 
Although DHP do have migrastatic activity in some mesenchymal-type OC cells, there has 
been no firm epidemiological evidence of increased survival in OC patients using DHP for co-
existing hypertension (Mason 1999). The main reason for this is likely a result of low plasma 
DHP concentration and subsequent concentration in ascitic fluid, which falls below the 
concentration required for migrastatic activity as outlined in the present work. The plasma 
concentration in patients taking 60 mg nifedipine is 367 nM, which falls below the 3 µM 
concentration shown for migrastatic activity in the present research. Further work should 
concentrate on in vivo trials that could determine whether intraperitoneal administration of 
DHP have any effect on formation of metastases in OC xenograft mice. Some studies have 
outlined the potential for intraperitoneal chemotherapy as a viable route of drug delivery in OC 
(Dehal, Smith, and Nash 2016) and this would likely be the route of administration with the 
highest efficacy in OC. 
While DHP antagonism of CaL did inhibit 2D migration in OVCAR-8 cells, chapter 6 of the 
present work showed no evidence of measurable CaV current in any OC cell line via 
electrophysiology or fluorescence imaging using Fluo4-AM, which was likely a result of the 
102 
 
low activation of CaV seen in Ca
2+ sparklets as discussed in section 6.4. However, TRP currents 
were identified in both the OC cell lines and MAF derived cells, lending support to other studies 
which have outlined the potential therapeutic benefit of targeting these channels in OC (Jing 
Wang et al. 2014). 
7.2 Overall conclusion 
 
The most important conclusion relating to the original research question as outlined in section 
1.7 was that DHP potently inhibit migration only in OC cells that exhibit mesenchymal type 
migration. This cell population includes cancer cells that have undergone EMT, and CAF – 
both of which are a motile, aggressive cell types that are responsible for formation of metastases 
in OC. 
Another important novel discovery of this work was that CaV1.2 is frequently nuclear expressed 
in OC cells from MAF. Given their nuclear expression of CaV1.2, it is likely that this channel 
has functions that relate to gene expression in MAF derived cancer cells.  
7.2.1 Future work 
 
In order to be able to view a complete picture of CaL expression in HGSOC progression, future 
studies should aim to measure expression of CaL in primary cells taken from STIC and omental 
metastases. If the theory that CaL are plasma membrane-expressed and targetable only in 
mesenchymal type OC cells is correct, then this data will be important in understanding 
whether intraperitoneal injection of DHP may be a potential treatment option, especially for 
late stage chemotherapy patients post-surgery. There is evidence to suggest that upon 
deposition onto abdominal surfaces, OC cells undergo a change in gene and protein expression 
that enables them to survive and proliferate in the new microenvironment (Hibbs et al. 2004) 
and CaL may play an important role in this process. 
For MAF derived cancer cells, in addition to determining CaV1.3 expression, it may also be 
possible to perform electrophysiological measurements of Ca2+ flux across isolated nuclear 
membranes. This first requires isolation of cancer cells, which can be achieved a number of 
ways, including via EpCAM-linked magnetic bead isolation (Q. Gao et al. 2019) or 
fluorescence-activated cell sorting (FACS) (Strauss et al. 2011). For this experiment it may 
also be useful to explore methods of OC spheroid dissociation, e.g. with trypsin (Shu Zhang et 
al. 2008). Isolation of nuclei can then be achieved by filtering homogenized cells through 
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cheesecloth then commencing rounds of homogenization and centrifugation, giving nuclear 
fractions with contamination by plasma membrane <5%, microsomes <1% and mitochondria 
<3% (Nicotera et al. 1989). Patch clamp electrophysiology can then be performed using low 
divalent cation solutions and micropipettes with high tip resistance (10-25 GΩ in 140 mM KCl 
solution) (Mak et al. 2013). 
Further research using mesenchymal OC cells should aim to record the presence of Ca2+ 
sparklets in these cells, which have been shown in other mesenchymally migrating cancer cells 
cell types to be facilitated by CaV and crucial for cell migration (Man et al. 2016). The most 
effective technique to measure Ca2+ sparklets is live cell fluorescence imaging, using either 
confocal or total internal reflection (TIRF) microscopy, which can give detailed information 
about the temporal and spatial distribution of these small Ca2+ signals (Santana and Navedo 
2013). 
The present study did not address any genetic contributions to CaL/TRP expression or function 
in OC, and future research could explore these to shed light on the role of these channels. This 
study did not address whether CaL/TRP channels were wild-type or mutant. Next-generation 
sequencing (NGS) could be used to assess whether channels have any particular mutation that 
may affect their function. Recent bioinformatics-based studies have shown that mutations in 
CACNA1C are associated with increased survival time in endometrial cancer and that this gene 
was broadly associated with cell-ECM adhesion and negative regulation of proliferation (Qiao 
et al. 2019). Other genetic aspects which could be explored are epigenetic factors affecting CaL 
expression as well as the contribution of copy number alterations to CaL/TRP expression – 
locus 12p13 is a commonly amplified region in OC that contains the gene for CACNA1C (Davis 
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